<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Genet</journal-id>
<journal-title-group>
<journal-title>Human Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0340-6717</issn>
<issn pub-type="epub">1432-1203</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27896429</article-id>
<article-id pub-id-type="pmc">5214768</article-id>
<article-id pub-id-type="publisher-id">1749</article-id>
<article-id pub-id-type="doi">10.1007/s00439-016-1749-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Copy number variability in Parkinson’s disease: assembling the puzzle through a <italic>systems biology</italic> approach</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>La Cognata</surname>
<given-names>Valentina</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morello</surname>
<given-names>Giovanna</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>D’Agata</surname>
<given-names>Velia</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cavallaro</surname>
<given-names>Sebastiano</given-names>
</name>
<address>
<phone>+39 095 7338111</phone>
<email>sebastiano.cavallaro@cnr.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label>Institute of Neurological Sciences, National Research Council, Catania, Italy </aff>
<aff id="Aff2"><label>2</label>Section of Human Anatomy and Histology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>28</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>136</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>37</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Parkinson’s disease (PD), the second most common progressive neurodegenerative disorder of aging, was long believed to be a non-genetic sporadic origin syndrome. The proof that several genetic loci are responsible for rare Mendelian forms has represented a revolutionary breakthrough, enabling to reveal molecular mechanisms underlying this debilitating still incurable condition. While single nucleotide polymorphisms (SNPs) and small indels constitute the most commonly investigated DNA variations accounting for only a limited number of PD cases, larger genomic molecular rearrangements have emerged as significant PD-causing mutations, including submicroscopic Copy Number Variations (CNVs). CNVs constitute a prevalent source of genomic variations and substantially participate in each individual’s genomic makeup and phenotypic outcome. However, the majority of genetic studies have focused their attention on single candidate-gene mutations or on common variants reaching a significant statistical level of acceptance. This gene-centric approach is insufficient to uncover the genetic background of polygenic multifactorial disorders like PD, and potentially masks rare individual CNVs that all together might contribute to disease development or progression. In this review, we will discuss literature and bioinformatic data describing the involvement of CNVs on PD pathobiology. We will analyze the most frequent copy number changes in familiar PD genes and provide a “<italic>systems biology</italic>” overview of rare individual rearrangements that could functionally act on commonly deregulated molecular pathways. Assessing the global genome-wide burden of CNVs in PD patients may reveal new disease-related molecular mechanisms, and open the window to a new possible genetic scenario in the unsolved PD puzzle.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1007/s00439-016-1749-4) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>
<institution>Italian Ministry of Education, Universities and Research</institution>
</funding-source>
<award-id>CTN01_00177_817708</award-id>
<principal-award-recipient>
<name>
<surname>Cavallaro</surname>
<given-names>Sebastiano</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag Berlin Heidelberg 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p>Parkinson’s disease (PD) is a progressive debilitating movement disorder, affecting approximately 1% of the population over 65 (Moore et al. <xref ref-type="bibr" rid="CR99">2005</xref>). The characteristic major motor symptoms derive from the profound and selective loss of dopaminergic neurons from <italic>substantia nigra pars compacta</italic>, coupled with an accumulation of round cytoplasmic inclusions (Lewy bodies) and dystrophic neurites (Lewy neurites) in surviving neurons (Moore et al. <xref ref-type="bibr" rid="CR99">2005</xref>). In more advanced stages, patients can also develop a range of nonmotor symptoms, including rapid eye movement, sleep behavior disorder, constipation, depression and cognitive decline. Treatments aimed at compensating dopamine deficit (such as levodopa and deep brain stimulation) can alleviate the motor symptoms but finally are not effective to halt or slow down disease progression (Toft and Ross <xref ref-type="bibr" rid="CR145">2010</xref>). Despite the molecular mechanisms underlying PD are still far from being understood, the progressive deterioration of vulnerable dopaminergic neurons seems to arise from several cellular disturbances including protein misfolding and aggregation (Michel et al. <xref ref-type="bibr" rid="CR97">2016</xref>), synaptic damages, apoptosis, mitochondrial dysfunctions (Winklhofer and Haass <xref ref-type="bibr" rid="CR158">2010</xref>), oxidative stress (Dias et al. <xref ref-type="bibr" rid="CR34">2013</xref>), impairment of the Ubiquitin/Proteasome System (UPS) (Betarbet et al. <xref ref-type="bibr" rid="CR8">2005</xref>) and neuroinflammation (Wang et al. <xref ref-type="bibr" rid="CR157">2015</xref>) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic representation of molecular elements and common altered pathways underlying the complex PD puzzle</p></caption><graphic id="MO1" xlink:href="439_2016_1749_Fig1_HTML"></graphic></fig>
</p>
<p>PD was for a long time believed to be a typical non-genetic disorder. When in 1997 Polymeropoulos and colleagues reported the first <italic>SNCA</italic> pathogenic mutation in the Italian Contursi kindred (Polymeropoulos et al. <xref ref-type="bibr" rid="CR120">1997</xref>), they revolutionized this view opening the way to new interesting perspectives about the genetic contribution to this still incurable condition (Moore et al. <xref ref-type="bibr" rid="CR99">2005</xref>). From that moment, an increasing number of genetic loci and numerous risk factors have been discovered (Lewis and Cookson <xref ref-type="bibr" rid="CR83">2012</xref>; Bonifati <xref ref-type="bibr" rid="CR12">2014</xref>), starting from the familiar genes responsible for the Mendelian inherited forms, such as the autosomal dominant genes (<italic>SNCA</italic>, <italic>LRRK2</italic>, <italic>VPS35</italic>, <italic>GBA</italic>), the typical recessive (<italic>PARK2</italic>, <italic>PINK1</italic>, <italic>PARK7</italic>) and the atypical recessive ones (<italic>ATP13A2</italic>, <italic>PLA2G6</italic>, <italic>FBXO7</italic>) (Klein and Westenberger <xref ref-type="bibr" rid="CR71">2012</xref>). Despite the existence of these rare monogenic forms, it is now clear that PD is a genetically heterogeneous and most likely complex disorder, often complicated by incomplete penetrant traits and variable expressivity. The list of candidate genes is continuously updated (Bonifati <xref ref-type="bibr" rid="CR12">2014</xref>; Lubbe and Morris <xref ref-type="bibr" rid="CR87">2014</xref>; Trinh and Farrer <xref ref-type="bibr" rid="CR146">2013</xref>), mainly thanks to the massive advancement in genomic biotechnologies that have allowed to detect hundreds of pathogenic or susceptibility variants at the single nucleotide polymorphism (SNP) level. However, a lot of work still has to be done to identify additional sources of missing heritability or to assign a precise causal mechanism to the growing number of discovered loci (Gamazon and Stranger <xref ref-type="bibr" rid="CR44">2015</xref>).</p>
<p>While SNPs and small indels constitute the most commonly investigated DNA variations, submicroscopic chromosomal rearrangements, also known as Copy Number Variations (CNVs), are emerging as crucial players in the individual’s genomic architecture and in modeling complex human diseases, including PD. However, the majority of CNV association studies have been conducted using the traditional candidate-gene approach that, although provides valuable information on common variants, is inadequate to completely dissect the genetic background of polygenic multifactorial disorders like PD. The search for single-gene mutations has to be changed, turning into the need to assess the collective effect of common and rare variants that together may converge on PD pathology. In this context, the “<italic>systems biology</italic>” approach represents a worthwhile instrument to analyze complex biological systems, moving beyond the conventional gene-centric scheme, and finally generating a more defined molecular picture of PD.</p>
<p>Herein, we will review the most common CNV-altered genes and detail the current knowledge about their pathogenic or susceptibility impact on PD pathobiology. Moreover, we will collect the set of rare individual CNVs reported so far in PD patients and analyze them by a “<italic>systems biology</italic>” approach. This new perspective reveals these private CNVs cluster in common deregulated biological processes that could contribute to disease onset or progression, and opens the window to a new possible genetic scenario in the unsolved PD puzzle.</p>
</sec>
<sec id="Sec2">
<title>Copy number variations: a prevalent source of genomic variations</title>
<p>The DNA sequence of human genome is constantly changing and this process allows humans to evolve and adapt. The scientific community has long been aware of genetic variations of extreme size (i.e., cytogenetically recognizable elements and SNPs) (Zarrei et al. <xref ref-type="bibr" rid="CR162">2015</xref>). However, about 10 years ago, scientists began to recognize abundant variations of an intermediate size class known as structural variations. Within this class, copy number variations represent the largest component by far. CNVs are defined as genomic segments showing copy number variability among individuals compared to a reference genome. The size of CNVs ranges from 50 bp to several Mb, with a significant drop of variant numbers in 50 bp to 1 kb range (MacDonald et al. <xref ref-type="bibr" rid="CR90">2014</xref>). These structural variants can include either a single gene or a contiguous set of genes, encompassing more polymorphic base pairs than SNPs and finally resulting in an altered DNA diploid status (i.e., gain or loss of genomic region).</p>
<p>Depending on their size, CNVs can be measured by a multitude of laboratory testing methods, either targeting the whole genome (genome-wide level) or restricted to certain locations on chromosomes (locus-specific levels) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>) (Cantsilieris et al. <xref ref-type="bibr" rid="CR21">2013</xref>). While targeted approaches such as FISH or quantitative PCR-based strategies have been long used in the past, the most advanced screenings rely on whole-genome applications, such as array Comparative Genomic Hybridization or Next-Generation Sequencing experiments. Both these biotechnologies have dramatically improved and catalyzed the detection and characterization of multiple CNVs, offering the simultaneous testing of thousands of loci with high reproducibility, high resolution, and scalability for complete mapping of imbalances (Carter et al. <xref ref-type="bibr" rid="CR22">2002</xref>; Shaw-Smith et al. <xref ref-type="bibr" rid="CR130">2004</xref>; Iafrate et al. <xref ref-type="bibr" rid="CR57">2004</xref>; Inazawa et al. <xref ref-type="bibr" rid="CR61">2004</xref>; Ishkanian et al. <xref ref-type="bibr" rid="CR64">2004</xref>). However, these whole-genome strategies still need post-experimental validations and, therefore, a gold-standard analysis for CNVs has not been defined yet.<fig id="Fig2"><label>Fig. 2</label><caption><p>CNVs can be measured by a spectrum of laboratory methods targeting specific locations on chromosomes (locus-specific levels), or the whole genome (genome-wide level). These numerous methodologies are characterized by different levels of resolutions. The locus-specific techniques encompass (1) PCR-based strategies, such as quantitative real-time PCR (qPCR), Multiplex Ligand Probe Amplification (MLPA) or multiplex amplifiable probe hybridization (MAPH); (2) the Fluorescence in situ Hybridization (FISH) assays and (3) the RFLP (restriction fragment length polymorphism—Southern blot analysis. The whole-genome methodologies include (1) the classical chromosomal G-bandage (karyotyping); (2) the aCGH (Comparative Genomic Hybridization array) platforms and (3) the NGS (Next-Generation sequencing) technology. These two latter are increasingly replacing both the classical detections methods and the locus-specific techniques</p></caption><graphic id="MO2" xlink:href="439_2016_1749_Fig2_HTML"></graphic></fig>
</p>
<p>CNVs are very common and arise in the presence of specific architectural genomic elements that render DNA regions very susceptible to rearrangements. Depending on whether the same rearrangement is identified in unrelated individuals, CNVs can be grouped as recurrent or non-recurrent events (Lee and Lupski <xref ref-type="bibr" rid="CR79">2006</xref>). The most common cause of recurrent genomic rearrangements is the non-allelic homologous recombination (NAHR) that occurs between two DNA blocks of high homology, like the region-specific low-copy repeats sequences (LCRs) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a). On the contrary, non-recurrent CNVs can result from non-homologous end joining (NHEJ) or fork stalling and template switching (FoSTeS) mechanisms. NHEJ represents the major cellular mechanism for double-strand break repair: upon a double-strand break, NHEJ reconnects chromosome ends leaving random nucleotides at the site of the breakage to facilitate the strands’ alignment and ligation (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b) (Ambroziak et al. <xref ref-type="bibr" rid="CR3">2015</xref>). FoSTeS occurs when the DNA replication machinery pauses, and the template is switched with another region in physical proximity to the original replication fork (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c) (Lee et al. <xref ref-type="bibr" rid="CR81">2007</xref>). Such template switching may occur several times before the replication process gets back to its original template, resulting in complex rearrangements (Ambroziak et al. <xref ref-type="bibr" rid="CR3">2015</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Schematic illustration of the three most common events causing genomic rearrangements. <bold>a</bold> NAHR generates CNVs when genomic segments with high sequence similarity (direct low-copy repeats sequences, <italic>green arrows</italic>) recombine. This recombination can generate a duplication of the similar locus (<italic>red arrow</italic>) on one chromosome, while removing the copy from the other. <bold>b</bold> Double-stranded breaks (DBS) in DNA sequence recruit NHEJ-associated proteins to repair and ligate DNA strands together. First, end-repair protein replaces lost nucleotides on the double-strand break and DNA ligase associates broken DNA fragments together. If fragments from different chromosomes ligate together, duplications or deletions of sequence can occur. <bold>c</bold> After the original stalling of the replication fork (<italic>black line</italic>), the lagging strand disengages and anneals to a second fork (<italic>blue line</italic>), followed by extension of the now ‘primed’ second fork and DNA synthesis. After the fork disengages, the tethered original fork with its lagging strand (<italic>black and blue lines</italic>) could invade a third fork (<italic>green line</italic>). Serial replication fork disengaging and lagging strand invasion could occur several times (e.g., FoSTeS × 2, FoSTeS × 3, etc.) before resumption of replication on the original template. It should be noted that the CNVs created through FoSTeS are difficult to be distinguished from those generated by micro-homology-mediated breakpoint-induced repair (MMBIR), a mechanism of end-joining that relies on small-scale homology of DNA sequence at the ends of DSBs</p></caption><graphic id="MO3" xlink:href="439_2016_1749_Fig3_HTML"></graphic></fig>
</p>
<p>CNVs can control phenotype in several ways: they can affect gene expression through the simple gene dosage effect, or through more intricate mechanisms such as insertions and deletions of regulatory regions and alterations of chromatin architecture (Gamazon and Stranger <xref ref-type="bibr" rid="CR44">2015</xref>). In this regard, CNVs can interfere with a form of regulatory scaffold of the chromatin (the so-called Topologically Associating Domains or TADs) by disrupting or repositioning boundaries and, therefore, constraining the enhancer or silencer activity with their target genes (Franke et al. <xref ref-type="bibr" rid="CR42">2016</xref>). Similarly, CNVs in other non-coding regions may alter the normal rate and tissue-specific transcription pattern of the neighboring, otherwise intact, genes by changing, for example, the affinity for transcription factors. This <italic>cis</italic>-<italic>acting</italic> effect of non-coding variations has been recently demonstrated for a SNP in a distal enhancer element regulating the expression of <italic>SNCA</italic> (Soldner et al. <xref ref-type="bibr" rid="CR138">2016</xref>). Some representative pictures about the mechanisms of non-coding variants and their implication in human genetics are reported in a number of excellent reviews (Spielmann and Mundlos <xref ref-type="bibr" rid="CR141">2016</xref>; Lupianez et al. <xref ref-type="bibr" rid="CR89">2016</xref>; Spielmann and Mundlos <xref ref-type="bibr" rid="CR140">2013</xref>), which the reader is referred to.</p>
<p>All together, CNV alterations may account for adaptive or behavioral traits, may have no phenotypic effects or can underlie diseases. For this reason, determining the clinical significance of CNVs is very challenging and comprehensively relies on frequency information from healthy control cohorts, hereditability, size, gene content, type (copy number state) and location on chromosome (interstitial, centromeric or repeat-regions) (Hehir-Kwa et al. <xref ref-type="bibr" rid="CR53">2013</xref>).</p>
<p>Notwithstanding the difficulties in interpreting quantitative data, specific large CNVs and single-gene dosage alterations have emerged as critical elements for the development and maintenance of the nervous system (Gu and Lupski <xref ref-type="bibr" rid="CR48">2008</xref>) and have appeared to contribute to hereditable or sporadic neurological diseases, such as neuropathies, epilepsy forms, autistic syndromes, psychiatric illnesses and also neurodegenerative diseases, including PD (Lee and Lupski <xref ref-type="bibr" rid="CR79">2006</xref>; Kalman and Vitale <xref ref-type="bibr" rid="CR66">2009</xref>; Hoyer et al. <xref ref-type="bibr" rid="CR55">2015</xref>; Olson et al. <xref ref-type="bibr" rid="CR112">2014</xref>; Grayton et al. <xref ref-type="bibr" rid="CR47">2012</xref>; Wang et al. <xref ref-type="bibr" rid="CR156">2013</xref>).</p>
<p>In the next paragraphs, we will focus on the current evidence about the occurrence of CNVs in familiar PD genes by highlighting strengths and weaknesses of interpretations for diagnosis and biomarkers usefulness. Moreover, we will collect from published literature the currently known set of rare CNVs observed in PD patients and analyze them through a <italic>systems biology</italic> point of view, in order to assess their biological role, their interactions and the possible functional impact on PD pathobiology.</p>
</sec>
<sec id="Sec3">
<title>Copy number variations in familiar PD genes</title>
<sec id="Sec4">
<title>
<italic>SNCA</italic>
</title>
<p>
<italic>SNCA</italic> (alpha-synuclein) represents the most convincing locus causing both familiar and sporadic PD. This gene encodes a small natively unfolded presynaptic protein that aggregates in Lewy bodies and Lewy neurites, the pathological hallmark lesions of PD (Stefanis <xref ref-type="bibr" rid="CR142">2012</xref>). As we will discuss here below, <italic>SNCA</italic> is the best example of dosage-dependent toxicity: the more alpha-synuclein you have, the worse will be PD.</p>
<p>The first genomic triplication of <italic>SNCA</italic> was observed within the Spellman–Muenter family (better known as Iowa Kindred), a large family with autosomal dominant inheritance transmission of PD and dementia (Singleton et al. <xref ref-type="bibr" rid="CR136">2003</xref>). Later, several families with different ethnic background have been described, including members carrying four copies (triplication) or three copies (duplication) of <italic>SNCA</italic> (Table <xref ref-type="table" rid="Tab1">1</xref>) (Wang et al. <xref ref-type="bibr" rid="CR156">2013</xref>; Keyser et al. <xref ref-type="bibr" rid="CR69">2010</xref>; Sekine et al. <xref ref-type="bibr" rid="CR128">2010</xref>; Kojovic et al. <xref ref-type="bibr" rid="CR74">2012</xref>; Darvish et al. <xref ref-type="bibr" rid="CR33">2013</xref>; Olgiati et al. <xref ref-type="bibr" rid="CR110">2015</xref>; Ferese et al. <xref ref-type="bibr" rid="CR41">2015</xref>; Uchiyama et al. <xref ref-type="bibr" rid="CR148">2008</xref>; Ahn et al. <xref ref-type="bibr" rid="CR1">2008</xref>; Nishioka et al. <xref ref-type="bibr" rid="CR106">2006</xref>, <xref ref-type="bibr" rid="CR107">2009</xref>; Chartier-Harlin et al. <xref ref-type="bibr" rid="CR24">2004</xref>; Ibanez et al. <xref ref-type="bibr" rid="CR58">2004</xref>, <xref ref-type="bibr" rid="CR59">2009</xref>; Sironi et al. <xref ref-type="bibr" rid="CR137">2010</xref>; Pankratz et al. <xref ref-type="bibr" rid="CR115">2011</xref>; Elia et al. <xref ref-type="bibr" rid="CR38">2013</xref>; Konno et al. <xref ref-type="bibr" rid="CR75">2016</xref>; Ross et al. <xref ref-type="bibr" rid="CR124">2008</xref>; Kara et al. <xref ref-type="bibr" rid="CR67">2014</xref>; Mutez et al. <xref ref-type="bibr" rid="CR104">2011</xref>). In general, triplication generates very high expression of mRNA and protein molecules and influences the clinical manifestations of PD, causing severe forms of Parkinsonism similar to dementia with Lewy body. In contrast, the clinical phenotype of patients with duplicated <italic>SNCA</italic> resembles idiopathic PD, mainly with late age at onset, good efficacy for levodopa therapy, slower disease progression and without early development of dementia.<table-wrap id="Tab1"><label>Table 1</label><caption><p>All the current studies describing <italic>SNCA</italic> copy number changes in PD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">CNVs in α-synuclein gene in PD</th></tr><tr><th align="left">CNV type</th><th align="left">Size</th><th align="left">Ethnicity</th><th align="left">Phenotype</th><th align="left">Methodology</th><th align="left">F–S–D</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Triplication (Spellman–Muenter family or Iowa Kindred)</td><td align="left">1.61–2.04 Mb</td><td align="left">Iowa</td><td align="left">PD and dementia with LBs</td><td align="left">qPCR, FISH</td><td align="left">F</td><td align="left">Singleton et al. (<xref ref-type="bibr" rid="CR136">2003</xref>)</td></tr><tr><td align="left">Duplication (Lister Family, branch J)</td><td align="left" rowspan="2">0.7987–0.9359 Mb</td><td align="left" rowspan="2">Sweden, United States</td><td align="left">Late-onset parkinsonism and early dysautonomia</td><td align="left" rowspan="2">qPCR; Microsatellite markers analysis; Affymetrix 250 K microarray</td><td align="left" rowspan="2">F</td><td align="left" rowspan="2">Farrer et al. (<xref ref-type="bibr" rid="CR40">2004</xref>), Fuchs et al. (<xref ref-type="bibr" rid="CR43">2007</xref>)</td></tr><tr><td align="left">Triplication (Lister Family, Swedish-America, Branch I)</td><td align="left">Early-onset parkinsonism with dementia and dysautonomia</td></tr><tr><td align="left">Duplication (Ikeuchi family)</td><td align="left" rowspan="2">5 Mb</td><td align="left" rowspan="2">Japan</td><td align="left" rowspan="2">Progressive parkinsonism with dementia with LBs</td><td align="left" rowspan="2">Microsatellite markers analysis, qPCR</td><td align="left" rowspan="2">F</td><td align="left" rowspan="2">Ikeuchi et al. (<xref ref-type="bibr" rid="CR60">2008</xref>)</td></tr><tr><td align="left">Homozygous duplication (Ikeuchi family—consanguineous marriage)</td></tr><tr><td align="left">Duplication (Uchiyama family)</td><td align="left">0.5–1.6 Mb</td><td align="left">Japan</td><td align="left">Parkinsonism with dementia with LBs</td><td align="left">qPCR</td><td align="left">F</td><td align="left">Uchiyama et al. (<xref ref-type="bibr" rid="CR148">2008</xref>)</td></tr><tr><td align="left" rowspan="2">Duplication</td><td align="left" rowspan="2">n.a.</td><td align="left" rowspan="2">Korea</td><td align="left">Early-onset parkinsonism with rapidly progressive course, cognitive impairment, and dysautonomia (Ahn family)</td><td align="left" rowspan="2">Semi-quantitative multiplex PCR, FISH</td><td align="left">F</td><td align="left" rowspan="2">Ahn et al. (<xref ref-type="bibr" rid="CR1">2008</xref>)</td></tr><tr><td align="left">Typical PD</td><td align="left">S</td></tr><tr><td align="left">Duplication</td><td align="left">n.a.</td><td align="left">Germany</td><td align="left">Early-onset parkinsonism</td><td align="left">qPCR, MLPA</td><td align="left">D</td><td align="left">Brueggemann et al. (<xref ref-type="bibr" rid="CR17">2008</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left">n.a.</td><td align="left">European and North African</td><td align="left">Early-onset PD</td><td align="left">MLPA, Microsatellite markers analysis</td><td align="left">S</td><td align="left">Troiano et al. (<xref ref-type="bibr" rid="CR147">2008</xref>)</td></tr><tr><td align="left">Duplication (Family A)</td><td align="left">0.6 Mb</td><td align="left" rowspan="7">Japan</td><td align="left" rowspan="7">Parkinsonism with or without dementia</td><td align="left" rowspan="7">Microsatellite markers analysis, qPCR, FISH, aCGH (BACS and Affymetrix)</td><td align="left" rowspan="7">F</td><td align="left" rowspan="7">Nishioka et al. (<xref ref-type="bibr" rid="CR107">2009</xref>), Nishioka et al. (<xref ref-type="bibr" rid="CR106">2006</xref>), Konno et al. (<xref ref-type="bibr" rid="CR75">2016</xref>), Kara et al. (<xref ref-type="bibr" rid="CR67">2014</xref>)</td></tr><tr><td align="left">Duplication (Family B)</td><td align="left">0.4 Mb</td></tr><tr><td align="left">Duplication (Family C)</td><td align="left">0.4 Mb</td></tr><tr><td align="left">Duplication (Family D)</td><td align="left">0.4 Mb</td></tr><tr><td align="left">Duplication (Family E)</td><td align="left">0.2 Mb</td></tr><tr><td align="left">Duplication (Family F)</td><td align="left">0.6 Mb</td></tr><tr><td align="left">Duplication (Family G)</td><td align="left">0.6 Mb</td></tr><tr><td align="left">Triplication (FPD-014) (Pat 011)</td><td align="left">2.61–2.64 Mb</td><td align="left" rowspan="5">France. Italy</td><td align="left">Atypical autosomal dominant parkinsonism</td><td align="left" rowspan="5">Semi-quantitative Multiplex PCR, Microsatellite analysis, Affymetrix GeneChip Human Mapping 250 K microarray (just for P59 family: FISH, 44 k CGH arrays Agilent)</td><td align="left" rowspan="5">F</td><td align="left" rowspan="5">Chartier-Harlin et al. (<xref ref-type="bibr" rid="CR24">2004</xref>), Ibanez et al. (<xref ref-type="bibr" rid="CR58">2004</xref>), Ibanez et al. (<xref ref-type="bibr" rid="CR59">2009</xref>), Ross et al. (<xref ref-type="bibr" rid="CR124">2008</xref>), Kara et al. (<xref ref-type="bibr" rid="CR67">2014</xref>), Mutez et al. (<xref ref-type="bibr" rid="CR104">2011</xref>)</td></tr><tr><td align="left">Duplication (FPD-131 o P59) (Pat 024-022-026)</td><td align="left">4.928 Mb</td><td align="left" rowspan="4">Typical autosomal dominant PD</td></tr><tr><td align="left">Duplication (FPD-321) (Pat 021)</td><td align="left">3.47–3.58 Mb</td></tr><tr><td align="left">Duplication (FPD-410) (Pat 001)</td><td align="left">0.63–0.65 Mb</td></tr><tr><td align="left">Duplication (FPD-437) (Pat 010-012)</td><td align="left">0.42–0.43 Mb</td></tr><tr><td align="left">Duplication (Sironi family)</td><td align="left">3.65 Mb</td><td align="left">Italy</td><td align="left">PD with progression to dementia</td><td align="left">MLPA, Agilent 105A chip</td><td align="left">F</td><td align="left">Sironi et al. (<xref ref-type="bibr" rid="CR137">2010</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left">n.a.</td><td align="left">Belgium</td><td align="left">Parkinsonian syndrome</td><td align="left">Multiplex amplicon quantification, qPCR</td><td align="left">S</td><td align="left">Nuytemans et al. (<xref ref-type="bibr" rid="CR108">2009</xref>)</td></tr><tr><td align="left">Triplication (Keyser family)</td><td align="left">n.a.</td><td align="left">South African (French–Italian origin)</td><td align="left">PD with dementia</td><td align="left">MLPA, qPCR</td><td align="left">F</td><td align="left">Keyser et al. (<xref ref-type="bibr" rid="CR69">2010</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left">n.a.</td><td align="left">Korea</td><td align="left">PD with cognitive dysfunction</td><td align="left">Semi-quantitative multiplex PCR</td><td align="left">S</td><td align="left">Shin et al. (<xref ref-type="bibr" rid="CR131">2010</xref>)</td></tr><tr><td align="left">Triplication</td><td align="left">n.a.</td><td align="left">Asian</td><td align="left">Early-onset and severe clinical features of parkinsonism</td><td align="left">qPCR, MLPA, microsatellite analysis</td><td align="left">F</td><td align="left">Sekine et al. (<xref ref-type="bibr" rid="CR128">2010</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left">3 Mb</td><td align="left">n.a.</td><td align="left">PD</td><td align="left">Illumina370Duo arrays</td><td align="left">F</td><td align="left">Pankratz et al. (<xref ref-type="bibr" rid="CR115">2011</xref>)</td></tr><tr><td align="left">Homozygous duplication</td><td align="left">0.928 Mb</td><td align="left">Pakistan</td><td align="left">Young-onset Parkinsonism</td><td align="left">MLPA, Nimblegen 135 K-array CGH</td><td align="left">F</td><td align="left">Kojovic et al. (<xref ref-type="bibr" rid="CR74">2012</xref>)</td></tr><tr><td align="left">Duplication (Partial Trisomy 4q)</td><td align="left">41.2 MB</td><td align="left">Belgium</td><td align="left">Young-onset, dopa-responsive parkinsonism</td><td align="left">Karyotype, aCGH, MLPA</td><td align="left">D</td><td align="left">Garraux et al. (<xref ref-type="bibr" rid="CR45">2012</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left">n.a.</td><td align="left">Non-Hispanic Caucasian</td><td align="left">Autosomal dominant Early-onset PD</td><td align="left">Customized 4 × 72 k format CGH microarrays by NimbleGen; Taqman qPCR</td><td align="left">F</td><td align="left">Wang et al. (<xref ref-type="bibr" rid="CR156">2013</xref>)</td></tr><tr><td align="left">Duplication (family Elia A)</td><td align="left">773 Kb</td><td align="left">Northern Argentina</td><td align="left">Early-onset PD that was variably associated with nonmotor features, such as dysautonomia, cognitive deficits, and psychiatric disturbances</td><td align="left" rowspan="2">MLPA, qPCR, Affymetrix high-resolution single nucleotide polymorphism-array analysis</td><td align="left" rowspan="2">F</td><td align="left" rowspan="2">Elia et al. (<xref ref-type="bibr" rid="CR38">2013</xref>)</td></tr><tr><td align="left">Duplication (Family Elia B)</td><td align="left">4820 Kb</td><td align="left">Italian</td><td align="left">Early-onset PD dementia with psychiatric disturbances to late-onset PD with mild cognitive impairment</td></tr><tr><td align="left">Duplication</td><td align="left">6.4 Mb</td><td align="left">Caucasian English</td><td align="left">Atypical clinical presentation strongly reminiscent of frontotemporal dementia and late-onset pallidopyramidal syndromes</td><td align="left">MLPA, aCGH Agilent 8 × 60 K</td><td align="left">F</td><td align="left">Kara et al. (<xref ref-type="bibr" rid="CR67">2014</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left" rowspan="2">n.a.</td><td align="left" rowspan="2">Iranian</td><td align="left">PD typical clinical features</td><td align="left" rowspan="2">MLPA, qPCR</td><td align="left" rowspan="2">F–S</td><td align="left" rowspan="2">Darvish et al. (<xref ref-type="bibr" rid="CR33">2013</xref>)</td></tr><tr><td align="left">Triplication</td><td align="left">PD with dementia</td></tr><tr><td align="left">Duplication (mosaicism)</td><td align="left">n.a.</td><td align="left">American mitochondrial haplogroup and European autosomal markers</td><td align="left">Early-onset Parkinsonism</td><td align="left">MLPA (no dosage alteration in buccal swab), FISH (no rearrangements in peripheral leukocytes; duplication—triplication in oral mucosa)</td><td align="left">F–S</td><td align="left">Perandones et al. (<xref ref-type="bibr" rid="CR116">2014</xref>)</td></tr><tr><td align="left">Duplication</td><td align="left">n.a.</td><td align="left">American</td><td align="left">Parkinsonism with LBs and Lewy neurites</td><td align="left">n.a.</td><td align="left">n.a.</td><td align="left">Konno et al. (<xref ref-type="bibr" rid="CR75">2016</xref>)</td></tr><tr><td align="left">Triplication</td><td align="left">1.3 Mb</td><td align="left">Italian</td><td align="left">Early-onset parkinsonism combined with depression, behavior disturbances, sleep disorders, and cognitive decline</td><td align="left">Genome-wide SNP microarrays, FISH, MLPA</td><td align="left">F</td><td align="left">Olgiati et al. (<xref ref-type="bibr" rid="CR110">2015</xref>)</td></tr><tr><td align="left">Triplication</td><td align="left">351 Kb</td><td align="left">Italian</td><td align="left">Severe parkinsonism featuring early-onset dyskinesia, psychiatric symptoms, and cognitive deterioration</td><td align="left">CGH-Array, MLPA, qPCR</td><td align="left">F</td><td align="left">Ferese et al. (<xref ref-type="bibr" rid="CR41">2015</xref>)</td></tr></tbody></table><table-wrap-foot><p>The CNVs mutation type, the size of the mutation, the ethnicity of patients, the phenotype and the methodological approaches to measure quantitative genomic variations are reported. The column F–S–D reports if described cases are familial, sporadic or de novo</p></table-wrap-foot></table-wrap>
</p>
<p>An interesting familiar pedigree, the “Lister family”, presents both duplicated and triplicated <italic>SNCA</italic> carriers within different branches of the pedigree (branches J and I), suggesting a primary duplication event followed later by another one and resulting in the triplication (Farrer et al. <xref ref-type="bibr" rid="CR40">2004</xref>; Fuchs et al. <xref ref-type="bibr" rid="CR43">2007</xref>). Similarly, the Ikeuchi family has both heterozygous and homozygous duplication carriers born from a consanguineous marriage (producing a pseudo-triplication) (Ikeuchi et al. <xref ref-type="bibr" rid="CR60">2008</xref>). The clinical features of individuals with the <italic>SNCA</italic> homozygous duplication showed severe parkinsonism similar to that of triplication carriers.</p>
<p>Along with the familiar forms, a good percentage of sporadic PD patients carry de novo duplication of <italic>SNCA</italic> (Table <xref ref-type="table" rid="Tab1">1</xref>) (Ahn et al. <xref ref-type="bibr" rid="CR1">2008</xref>; Garraux et al. <xref ref-type="bibr" rid="CR45">2012</xref>; Shin et al. <xref ref-type="bibr" rid="CR131">2010</xref>; Troiano et al. <xref ref-type="bibr" rid="CR147">2008</xref>; Brueggemann et al. <xref ref-type="bibr" rid="CR17">2008</xref>; Nuytemans et al. <xref ref-type="bibr" rid="CR108">2009</xref>). Generally, their clinical course is similar to typical sporadic PD without severe progression or cognitive decline.</p>
<p>The breakpoint of <italic>SNCA</italic> multiplications is not the same in each patient. The largest multiplication detected so far is about 41.2 Mb, containing 150 genes and defined a partial trisomy 4q (Garraux et al. <xref ref-type="bibr" rid="CR45">2012</xref>), while the smallest one counts about 0.2 Mb (Nishioka et al. <xref ref-type="bibr" rid="CR107">2009</xref>). The size and gene makeup of each multiplicated region do not seem to severely influence the clinical presentation of the carriers.</p>
<p>Interesting insights derive from the mosaicism condition of <italic>SNCA</italic> rearrangements. In this regard, two interesting PD cases have been described, which resulted negative to exon dosage test in peripheral blood, and positive for <italic>SNCA</italic> copy number changes on oral mucosa cells (Perandones et al. <xref ref-type="bibr" rid="CR116">2014</xref>). Both patients displayed a parkinsonian clinical phenotype of <italic>SNCA</italic> copy number carriers. Starting from this evidence, authors suggest to take into consideration the possibility to examine cells from both peripheral lymphocytes and other tissues to detect low-grade mosaicism.</p>
</sec>
<sec id="Sec5">
<title>
<italic>PARK2</italic>
</title>
<p>Although <italic>SNCA</italic> story suggests a gain of function, several early-onset forms of PD have demonstrated the role of loss of function genes in the etiology of the disease. The most common loss-of-function mutations belong to Parkin (or <italic>PARK2</italic>) gene, one of the largest in our genome harbored in the long arm of chromosome 6 (6q25.2-q27) and encoding an E3 ubiquitin ligase. Mutations of <italic>PARK2</italic> are particularly frequent in individuals with familiar recessive inheritance and account for 50% of the cases with autosomal recessive juvenile PD. Parkin mutations also explain ~15% of the sporadic cases with onset before 45 (Bonifati <xref ref-type="bibr" rid="CR11">2012</xref>; Lucking et al. <xref ref-type="bibr" rid="CR88">2000</xref>) and act as susceptibility alleles for late-onset forms of PD (2% of cases) (Oliveira et al. <xref ref-type="bibr" rid="CR111">2003</xref>).</p>
<p>
<italic>PARK2</italic> gene has a high mutation rate because it is located in the <italic>core</italic> of FRA6E site, one of the most mutation-susceptible common fragile sites of human genome (Ambroziak et al. <xref ref-type="bibr" rid="CR3">2015</xref>). For this reason, more than 200 putative pathogenic mutations have been reported so far, affecting numerous ethnic populations (Wang et al. <xref ref-type="bibr" rid="CR155">2010</xref>, <xref ref-type="bibr" rid="CR156">2013</xref>; Keyser et al. <xref ref-type="bibr" rid="CR69">2010</xref>; Nuytemans et al. <xref ref-type="bibr" rid="CR108">2009</xref>; Chaudhary et al. <xref ref-type="bibr" rid="CR25">2006</xref>; Klein et al. <xref ref-type="bibr" rid="CR73">2005</xref>; Shadrina et al. <xref ref-type="bibr" rid="CR129">2007</xref>; Choi et al. <xref ref-type="bibr" rid="CR30">2008</xref>; Pankratz et al. <xref ref-type="bibr" rid="CR114">2009</xref>; Kay et al. <xref ref-type="bibr" rid="CR68">2010</xref>; Guerrero Camacho et al. <xref ref-type="bibr" rid="CR49">2012</xref>; Moura et al. <xref ref-type="bibr" rid="CR100">2012</xref>; Yonova-Doing et al. <xref ref-type="bibr" rid="CR160">2012</xref>; Chu et al. <xref ref-type="bibr" rid="CR31">2014</xref>; Al-Mubarak et al. <xref ref-type="bibr" rid="CR2">2015</xref>; Guo et al. <xref ref-type="bibr" rid="CR51">2015</xref>; Mata et al. <xref ref-type="bibr" rid="CR95">2005</xref>). The <italic>PARK2</italic> mutation spectrum includes homozygous or compound heterozygous missense and nonsense point mutations, as well as several exon rearrangements (both duplications and deletions) involving all the originally cloned 12 exons and the promoter region. Recently, our research group has outlined a complex alternative splicing mechanism regulating the expression of <italic>PARK2</italic> (La Cognata et al. <xref ref-type="bibr" rid="CR77">2014</xref>, <xref ref-type="bibr" rid="CR78">2016</xref>; Scuderi et al. <xref ref-type="bibr" rid="CR127">2014</xref>). These data suggest that five additional exons exist, which, however, have never been considered for mutational or dosage screening. Overall, currently known Parkin CNVs are summarized in Fig. <xref ref-type="fig" rid="Fig4">4</xref> and are collected in the Parkinson Disease Mutation database (<ext-link ext-link-type="uri" xlink:href="http://www.molgen.vib-ua.be/PDMutDB">http://www.molgen.vib-ua.be/PDMutDB</ext-link>), which the reader is referred to for more details.<fig id="Fig4"><label>Fig. 4</label><caption><p>Schematic representation of <italic>PARK2</italic> genetic structure and currently identified CNVs in PD patients. All the canonical <italic>PARK2</italic> exons are involved in exons rearrangements. <italic>Red bars</italic> correspond to exons deletions, <italic>blue bars</italic> to duplications and <italic>green bars</italic> to triplications. All depicted CNVs can be found at the Parkinson Disease Mutation database (<ext-link ext-link-type="uri" xlink:href="http://www.molgen.vib-ua.be/PDMutDB">http://www.molgen.vib-ua.be/PDMutDB</ext-link>)</p></caption><graphic id="MO4" xlink:href="439_2016_1749_Fig4_HTML"></graphic></fig>
</p>
<p>CNV rearrangements involving <italic>PARK2</italic> exons account for 50–60% of all pathogenic anomalies, rendering gene dosage assays essential in parkin mutational screening (Kim et al. <xref ref-type="bibr" rid="CR70">2012</xref>). However, the <italic>hotspot</italic> nature of this gene makes its quantitative analysis a particular challenge, and several issues need to be pointed out in this regard. First, the determination of mutational phase of the rearrangements, meaning the assessment that amplified or deleted exons are really contiguous. Phase determination seems to be a fundamental requisite for <italic>PARK2</italic> molecular diagnosis: by phase determination, several patients with apparent contiguous multi-exon deletions were re-diagnosed as compound heterozygotes (Kim et al. <xref ref-type="bibr" rid="CR70">2012</xref>). A second important point refers to breakpoint mapping which can be useful to compare exon rearrangements between patients and families and to study the possible causing event mechanism (Elfferich et al. <xref ref-type="bibr" rid="CR37">2011</xref>). Just a few number of papers have addressed this issue so far, but mostly report rearrangements into the region between <italic>PARK2</italic> exons 2 and 8 (Ambroziak et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Elfferich et al. <xref ref-type="bibr" rid="CR37">2011</xref>). In the majority of mapped cases, micro-homologies at breakpoint junctions were present, thus supporting NHEJ and FoSTeS as the major mechanisms responsible for <italic>PARK2</italic> genomic rearrangements (Ambroziak et al. <xref ref-type="bibr" rid="CR3">2015</xref>). Moreover, some data underpin the possible effects of ancient common founder in minor ethnic groups (Periquet et al. <xref ref-type="bibr" rid="CR118">2001</xref>). For example, microsatellite markers analysis in four families from The Netherlands have shown that a common haplotype of 1.2 Mb could be distinguished for the exon 7 duplication and a common haplotype of 6.3 Mb for the deletion of exon 4, suggesting common founder effects for distinct large rearrangements in parkin (Elfferich et al. <xref ref-type="bibr" rid="CR37">2011</xref>).</p>
<p>A relevant matter of ongoing debates is the pathogenic role of single heterozygous <italic>PARK2</italic> CNVs. Several studies have sought to address this issue, but the findings published so far are controversial and conflicting. Some reports indicate that CNVs heterozygous mutations in <italic>PARK2</italic> associate with increased PD risk (Pankratz et al. <xref ref-type="bibr" rid="CR115">2011</xref>; Pankratz et al. <xref ref-type="bibr" rid="CR114">2009</xref>; Huttenlocher et al. <xref ref-type="bibr" rid="CR56">2015</xref>), while others found no differences for association (Wang et al. <xref ref-type="bibr" rid="CR156">2013</xref>; Kay et al. <xref ref-type="bibr" rid="CR68">2010</xref>). In addition, examinations of family pedigrees revealed heterozygous members with mild late-onset PD (Klein et al. <xref ref-type="bibr" rid="CR72">2000</xref>; Farrer et al. <xref ref-type="bibr" rid="CR39">2001</xref>), or without typical clinical signs of the disease (Wang et al. <xref ref-type="bibr" rid="CR156">2013</xref>).</p>
</sec>
<sec id="Sec6">
<title>
<italic>PINK1</italic>
</title>
<p>Pathogenic mutations in <italic>PINK1</italic> (PTEN-induced kinase gene) are a less common cause of early-onset PD with a frequency variable from 1 to 9% depending on the ethnic background (Pogson et al. <xref ref-type="bibr" rid="CR119">2011</xref>). The encoded protein is a putative serine/threonine kinase of 581 amino acids involved in mitochondrial quality control and oxidative stress (Valente et al. <xref ref-type="bibr" rid="CR149">2004</xref>).</p>
<p>Homozygous and compound heterozygous deletions involving different combinations of exons 4–8 have been described in both familial and sporadic early-onset cases coming from Japan, Brazil, Sudan and Iran (Table <xref ref-type="table" rid="Tab2">2</xref>) (Darvish et al. <xref ref-type="bibr" rid="CR33">2013</xref>; Atsumi et al. <xref ref-type="bibr" rid="CR5">2006</xref>; Li et al. <xref ref-type="bibr" rid="CR84">2005</xref>; Camargos et al. <xref ref-type="bibr" rid="CR20">2009</xref>; Cazeneuve et al. <xref ref-type="bibr" rid="CR23">2009</xref>). A breakpoint analysis has been performed just in one of these patients, revealing a complex rearrangement involving the neighboring <italic>DDOST</italic> gene and maybe resulting from FoSTeS mechanism (Cazeneuve et al. <xref ref-type="bibr" rid="CR23">2009</xref>). Moreover, single heterozygous cases have been described, albeit these mutations do not completely explain the recessive inheritance pattern. The largest heterozygous deletion known so far (56 kb) includes the entire <italic>PINK1</italic> genetic region, two neighboring genes, and two highly similar AluJo repeat sequences, which have been suggested as responsible for an unequal crossing-over (Marongiu et al. <xref ref-type="bibr" rid="CR93">2007</xref>). Further heterozygous deletions involving exons 1, 3–8 and exon 7 have been described in familial or sporadic cases of early-onset PD (Table <xref ref-type="table" rid="Tab2">2</xref>) (Moura et al. <xref ref-type="bibr" rid="CR100">2012</xref>; Guo et al. <xref ref-type="bibr" rid="CR50">2010</xref>; Samaranch et al. <xref ref-type="bibr" rid="CR126">2010</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>All the current studies describing <italic>PINK1</italic> copy number changes in PD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">CNVs overlapping PINK1 gene in PD</th></tr><tr><th align="left">CNV type</th><th align="left">Size</th><th align="left">Ethnicity</th><th align="left">Phenotype</th><th align="left">Methodology</th><th align="left">F–S</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Homoz. deletion</td><td align="left">Exons 6–8</td><td align="left">Japan</td><td align="left">Early-onset PD + dementia</td><td align="left">n.a.</td><td align="left">F</td><td align="left">Li et al. (<xref ref-type="bibr" rid="CR84">2005</xref>)</td></tr><tr><td align="left">Homoz. deletion</td><td align="left">~4600 bp</td><td align="left">Japan</td><td align="left">Early-onset PD</td><td align="left">n.a.</td><td align="left">n.a.</td><td align="left">Atsumi et al. (<xref ref-type="bibr" rid="CR5">2006</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">~56 kb</td><td align="left">Italy</td><td align="left">Definite PD</td><td align="left">qPCR, FISH, Microsatellite markers analysis</td><td align="left">S</td><td align="left">Marongiu et al. (<xref ref-type="bibr" rid="CR93">2007</xref>)</td></tr><tr><td align="left">Homoz. deletion</td><td align="left">Exon 7</td><td align="left">Brazil</td><td align="left">Early-onset PD</td><td align="left">Sequencing, qPCR</td><td align="left">S</td><td align="left">Camargos et al. (<xref ref-type="bibr" rid="CR20">2009</xref>)</td></tr><tr><td align="left">Homoz. deletion</td><td align="left">8669 bp (exons 4–8)</td><td align="left">Sudan</td><td align="left">Early-onset PD</td><td align="left">MLPA, sequencing</td><td align="left">F</td><td align="left">Cazeneuve et al. (<xref ref-type="bibr" rid="CR23">2009</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">Exons 3-8</td><td align="left">China</td><td align="left">Early-onset PD</td><td align="left">qPCR</td><td align="left">S</td><td align="left">Guo et al. (<xref ref-type="bibr" rid="CR50">2010</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">Exon 7</td><td align="left">Spanish</td><td align="left">Early-onset PD with LBs</td><td align="left">Sequencing, qPCR</td><td align="left">F</td><td align="left">Samaranch et al. (<xref ref-type="bibr" rid="CR126">2010</xref>)</td></tr><tr><td align="left">Compound heteroz. deletion</td><td align="left">Exon 2 + exons 2–4</td><td align="left" rowspan="2">Iran</td><td align="left">Typical clinical features</td><td align="left" rowspan="2">MLPA, qPCR</td><td align="left">S</td><td align="left" rowspan="2">Darvish et al. (<xref ref-type="bibr" rid="CR33">2013</xref>)</td></tr><tr><td align="left">Homoz. deletion</td><td align="left">Exon 5 and exon 4</td><td align="left">Typical clinical features and PD with dementia</td><td align="left">F</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">Exon 1</td><td align="left">Brazil</td><td align="left">Early-onset PD</td><td align="left">MLPA, qPCR</td><td align="left">n.a.</td><td align="left">Moura et al. (<xref ref-type="bibr" rid="CR100">2012</xref>)</td></tr></tbody></table><table-wrap-foot><p>The CNVs mutation type, the size of the mutation, the ethnicity of patients, the phenotype and the methodological approaches to measure quantitative genomic variations are reported. The column F–S reports if described cases are familial or sporadic</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec7">
<title>
<italic>PARK7</italic>
</title>
<p>
<italic>PARK7</italic> was the third gene identified in 2001 as responsible of early-onset PD (Bonifati et al. <xref ref-type="bibr" rid="CR13">2003</xref>; van Duijn et al. <xref ref-type="bibr" rid="CR152">2001</xref>). It encodes a conserved multifunctional protein belonging to the peptidase C56 family (also called DJ1) which acts as a positive regulator of transcription, redox-sensitive chaperone, sensor for oxidative stress, and apparently protects neurons from ROS-induced apoptosis (Lev et al. <xref ref-type="bibr" rid="CR82">2006</xref>; Ariga et al. <xref ref-type="bibr" rid="CR4">2013</xref>; Xu et al. <xref ref-type="bibr" rid="CR159">2005</xref>).</p>
<p>The proof that <italic>PARK7</italic> was a gene-causing disease came from a study on a Dutch family where members carried a 14 kb homozygous deletion involving the first five of seven exons (Bonifati et al. <xref ref-type="bibr" rid="CR13">2003</xref>). Later, three siblings of Iranian origins born from consanguineous parents and carriers of a homozygous deletion of exon 5 have been reported (Table <xref ref-type="table" rid="Tab3">3</xref>) (Darvish et al. <xref ref-type="bibr" rid="CR33">2013</xref>). Further heterozygous CNVs (both deletions and duplication) involving the exons of <italic>DJ</italic>-<italic>1</italic> gene have been published so far (Guo et al. <xref ref-type="bibr" rid="CR50">2010</xref>; Hedrich et al. <xref ref-type="bibr" rid="CR52">2004</xref>; Djarmati et al. <xref ref-type="bibr" rid="CR35">2004</xref>; Macedo et al. <xref ref-type="bibr" rid="CR91">2009</xref>), although they do not completely explain the recessive pattern of the PD phenotype.<table-wrap id="Tab3"><label>Table 3</label><caption><p>All the current studies describing <italic>PARK7</italic> copy number changes in PD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">CNVs overlapping PARK7 gene in PD</th></tr><tr><th align="left">CNV type</th><th align="left">Size</th><th align="left">Ethnicity</th><th align="left">Phenotype</th><th align="left">Methodology</th><th align="left">F vs. S</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Homoz. deletion</td><td align="left">Exons 1–5 (14.082 bp)</td><td align="left">Dutch</td><td align="left">Autosomal recessive early-onset Parkinsonism</td><td align="left">Microsatellite markers analysis, cloning, PCR, sequencing</td><td align="left">F</td><td align="left">Bonifati et al. (<xref ref-type="bibr" rid="CR13">2003</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">Exons 5–7</td><td align="left">Caucasian (Tyrol, Austria)</td><td align="left">Early-onset PD</td><td align="left">Quantitative duplex PCR</td><td align="left">S</td><td align="left">Hedrich et al. (<xref ref-type="bibr" rid="CR52">2004</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">Exon 5</td><td align="left">Serbian</td><td align="left">Early-onset PD</td><td align="left">qPCR</td><td align="left">n.a.</td><td align="left">Djarmati et al. (<xref ref-type="bibr" rid="CR35">2004</xref>)</td></tr><tr><td align="left">Heteroz. duplication</td><td align="left">Exons 1–5</td><td align="left">Dutch</td><td align="left">Early-onset PD</td><td align="left">MLPA, sequencing</td><td align="left">S</td><td align="left">Macedo et al. (<xref ref-type="bibr" rid="CR91">2009</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">Exon 2</td><td align="left">China</td><td align="left">Early-onset PD</td><td align="left">qPCR</td><td align="left">S</td><td align="left">Guo et al. (<xref ref-type="bibr" rid="CR50">2010</xref>)</td></tr><tr><td align="left">Homoz. deletion</td><td align="left">Exon 5</td><td align="left">Iran</td><td align="left">Typical clinical features</td><td align="left">MLPA, qPCR</td><td align="left">F</td><td align="left">Darvish et al. (<xref ref-type="bibr" rid="CR33">2013</xref>)</td></tr></tbody></table><table-wrap-foot><p>The CNVs mutation type, the size of the mutation, the ethnicity of patients, the phenotype and the methodological approaches to measure quantitative genomic variations are reported. The column F–S reports if described cases are familial or sporadic</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec8">
<title>
<italic>ATP13A2</italic>
</title>
<p>
<italic>ATP13A2</italic> mutations are associated with Kufor-Rakeb syndrome (KRS), a form of recessively levodopa-responsive inherited atypical Parkinsonism (Vilarino-Guell et al. <xref ref-type="bibr" rid="CR154">2009</xref>). This gene encodes a large protein belonging to the ATPase transmembrane transporters, and recently it has been identified as a potent modifier of the toxicity induced by alpha-synuclein (Murphy et al. <xref ref-type="bibr" rid="CR103">2013</xref>). To our knowledge, just one family from Iran with deletion of <italic>ATP13A2</italic> has been reported, including three affected siblings born from consanguineous parents and carriers of a homozygous deletion of exon 2 (Darvish et al. <xref ref-type="bibr" rid="CR33">2013</xref>). All three individuals presented moderate mental retardation, aggressive behaviors, visual hallucinations, supranuclear vertical gaze paresis, slow vertical saccades and dystonia. Cognitive function deteriorated rapidly, and all of them developed dementia by age 10. Further clinical and genetic follow-up of KRS patients will increase the knowledge of the natural history and clinical features of this syndrome.</p>
</sec>
</sec>
<sec id="Sec9">
<title>The 22q11.2 deletion</title>
<p>A separate speech deserves the 22q11.2 deletion that lately is receiving more and more attention in PD field. Deletions at 22q11.2 are classically associated with a heterogeneous range of clinical syndromes, overall named 22q deletion syndrome (22qDS). The clinical phenotype of 22q deletion carriers varies widely, with multiple system involvement, including cleft palate, dysmorphic facial features, cardiac defects, skeletal deformities, developmental delays, learning disabilities and increased risk of developing schizophrenia and other mental disorders. Despite the multiple system involvement, the association between 22q11.2 deletion and PD was not suspected until the publication of independent case reports of co-occurrence of parkinsonism in patients with 22q11.2 deletion syndrome (Table <xref ref-type="table" rid="Tab4">4</xref>) (Krahn et al. <xref ref-type="bibr" rid="CR76">1998</xref>; Zaleski et al. <xref ref-type="bibr" rid="CR161">2009</xref>; Booij et al. <xref ref-type="bibr" rid="CR14">2010</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>All the currently studies describing 22q11.2 deletions in PD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="7">CNVs involving the 22q11.2 region</th></tr><tr><th align="left">CNV type</th><th align="left">Size</th><th align="left">Ethnicity</th><th align="left">Phenotype</th><th align="left">Methodology</th><th align="left">Familial vs. sporadic</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Heteroz. deletion</td><td align="left">n.a.</td><td align="left">n.a.</td><td align="left">Childhood-onset schizophrenia associated with parkinsonism</td><td align="left">FISH</td><td align="left">No family history</td><td align="left">Krahn et al. (<xref ref-type="bibr" rid="CR76">1998</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">3 Mb including COMT gene</td><td align="left">n.a.</td><td align="left">22qDS + early onset PD</td><td align="left">FISH</td><td align="left">No family history</td><td align="left">Zaleski et al. (<xref ref-type="bibr" rid="CR161">2009</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">n.a.</td><td align="left">n.a.</td><td align="left">22qDS + PD (PD was considered a side effect of neuroleptic treatment or a clinical feature of early-onset PD)</td><td align="left">FISH</td><td align="left">n.a.</td><td align="left">Booij et al. (<xref ref-type="bibr" rid="CR14">2010</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">From 15 to 3 Mb</td><td align="left">Canada</td><td align="left">22qDS + early-onset PD confirmed by neuropathological examination</td><td align="left">FISH, quantitative real-time PCR</td><td align="left">No family history</td><td align="left">Butcher et al. (<xref ref-type="bibr" rid="CR18">2013</xref>)</td></tr><tr><td align="left">Mosaicism</td><td align="left">n.a.</td><td align="left">Ashkenazi Jewish</td><td align="left">Midline defects and PD</td><td align="left">FISH</td><td align="left">Familial</td><td align="left">Perandones et al. (<xref ref-type="bibr" rid="CR117">2015</xref>)</td></tr><tr><td align="left">Heteroz. deletion</td><td align="left">2.88 Mb</td><td align="left">n.a.</td><td align="left">22q11.2DS + PD, dopa responsive</td><td align="left">aCGH</td><td align="left">Proband’s father developed PD in later life</td><td align="left">Rehman et al. (<xref ref-type="bibr" rid="CR123">2015</xref>)</td></tr><tr><td align="left">Deletion</td><td align="left">Eight patients, whose deletion ranged around 3 Mb</td><td align="left">n.a.</td><td align="left">Both early-onset and late-onset PD with typical motor signs and response to L-DOPA</td><td align="left">Metanalysis of four previous independent studies and validation with CytoSure 15 K-Array</td><td align="left">n.a.</td><td align="left">Mok et al. (<xref ref-type="bibr" rid="CR98">2016</xref>)</td></tr></tbody></table><table-wrap-foot><p>The CNVs mutation type, the size of the mutation, the ethnicity of patients, the phenotype and the methodological approaches to measure quantitative genomic variations are reported. The column familial vs. sporadic reports if described cases are familial or sporadic PD</p></table-wrap-foot></table-wrap>
</p>
<p>The interest in this possible link increased after Butcher and colleagues reported four patients with early-onset PD in their study of 159 adults with 22q11.2 deletion syndrome, founding that the use of antipsychotics in these patients delayed diagnosis of PD, and assessing after autopsy examination the presence of typical Lewy bodies and Lewy neurite formations too (Butcher et al. <xref ref-type="bibr" rid="CR18">2013</xref>). A couple of months ago, Mok et al. (Mok et al. <xref ref-type="bibr" rid="CR98">2016</xref>) performed the reverse experiment, namely pooling data from previous large PD case–control studies and assessing the frequency of 22q11.2 deletion carriers. Eight patients with PD and none of the controls had the deletion, providing a statistical significant association between the 22q deletion and an increased risk of developing the disease (Table <xref ref-type="table" rid="Tab4">4</xref>). In accordance with this result, a single case report from Virginia describes a 37-year-old early-onset PD patient carrying the 22q11.2 deletion but without any features of typical 22qDS (Rehman et al. <xref ref-type="bibr" rid="CR123">2015</xref>). All together, this evidence suggests 22q11.2 deletion might underlie early-onset PD, warning clinicians to take into consideration this genetic test as part of their evaluation for patients with early-onset PD.</p>
<p>The chromosome 22q11.2 region contains some excellent candidate genes for PD: <italic>COMT</italic> (or Catechol-O-Methyltransferase), a key regulator of synaptic dopamine levels and a target of inhibitory drugs for the treatment of wearing-off phenomena in PD patients (Muller <xref ref-type="bibr" rid="CR101">2015</xref>); <italic>SEPT5</italic>, a vesicle- and membrane-associated protein playing a significant role in inhibiting exocytosis, as well as a parkin substrate (Son et al. <xref ref-type="bibr" rid="CR139">2005</xref>; Marttinen et al. <xref ref-type="bibr" rid="CR94">2015</xref>); <italic>DGCR8</italic> that encodes a complex subunit involved in the biogenesis of microRNAs, including miR-185 which is predicted to target <italic>LRRK2</italic> (Ogaki and Ross <xref ref-type="bibr" rid="CR109">2014</xref>).</p>
<p>Interestingly, Perandones et al. (<xref ref-type="bibr" rid="CR117">2015</xref>) reported a case of mosaicism of a patient from the Ashkenazi Jewish ethnic group with a history of midline defects and PD onset at 46 years (Table <xref ref-type="table" rid="Tab4">4</xref>). In this patient, FISH test detected a mosaicism of the 22q deletion in 24% of the analyzed blood cells, highlighting the relevance of performing individual cell-by-cell analysis.</p>
</sec>
<sec id="Sec10">
<title>High-throughput whole-genome studies to map CNVs in PD</title>
<p>The major reported PD-linked CNVs have actually been ascertained through single-gene investigations, and received most of the attention because of their already-known or hypothesized role in the disease. However, these mutations account only for a limited number of PD, and the vast majority of cases continue to remain without a valid explanation. Thanks to the rapid advancement of biotechnologies, scientists are now able to scan entirely the human genome, producing high-quality ultradense genotypes and fast localization of genomic deletions and duplications. However, their applications in PD field are still not numerous, and only a few studies have investigated the overall contribution of global CNVs on PD etiology (Pankratz et al. <xref ref-type="bibr" rid="CR115">2011</xref>; Simon-Sanchez et al. <xref ref-type="bibr" rid="CR133">2008</xref>; Liu et al. <xref ref-type="bibr" rid="CR86">2013</xref>; Pamphlett et al. <xref ref-type="bibr" rid="CR113">2012</xref>; Bademci et al. <xref ref-type="bibr" rid="CR6">2010</xref>).</p>
<p>The first pilot analysis assessing the role of structural genetic variations in risk for PD was carried out in a population of 276 unique and unrelated Caucasian individual with PD using two genome-wide SNP genotyping platforms and corrected metrics for CNVs interpretation (Simon-Sanchez et al. <xref ref-type="bibr" rid="CR133">2008</xref>). In this study, along with several <italic>PARK2</italic> deletions and duplications confirmed by independent gene dosage experiments, a total of 182 genomic duplications and 161 heterozygous/homozygous deletions were measured, but no statistically significant regions associated with PD were identified. Among these CNVs, a subgroup (38 duplications and 44 deletions) was revealed only in patients and not in healthy controls or in DGV repository (<ext-link ext-link-type="uri" xlink:href="http://dgv.tcag.ca/dgv/app/home">http://dgv.tcag.ca/dgv/app/home</ext-link>), a web database collecting CNV alterations observed in the normal population (Supplementary Table 1).</p>
<p>Some years later, Pankratz et al. (<xref ref-type="bibr" rid="CR115">2011</xref>) presented the results of a systematic CNV genome-wide analysis performed using two CNV calling algorithms (PennCNV and QuantiSNP), two different association strategies (centric position and 400 kb window) and multiple filters to improve the quality of CNVs calls. By intersection of results from all these criteria, they were able to replicate the association of PD susceptibility with <italic>PARK2</italic> CNVs, and then revealed two novel genes (<italic>DOCK5</italic> and <italic>USP32</italic>) associated with an increase in risk for PD at genome-wide significance (unfortunately not confirmed by independent molecular tests). Also in this study, a set of altered genetic regions were unique of PD patients (Supplementary Table 1).</p>
<p>To identify novel CNVs and to evaluate their contribution to PD, Liu et al. (<xref ref-type="bibr" rid="CR86">2013</xref>) conducted a CNVs genome-wide scan in a case–control dataset (268 PD cases and 178 controls), focusing on a genetic isolate, the Ashkenazi Jewish population. Using high-confidence CNVs, they examined the global genome-wide burden of large and rare CNVs: this analysis did not reveal significant differences between cases and controls, but deletions were found 1.4 times more often in cases than controls. Interestingly, several rare genic CNVs were present in patients and absent in controls (Supplementary Table 1). Among these, the duplication of <italic>OVOS2</italic> (ovostatin 2, a gene of unknown function) was classified as significant risk factors for PD. Other interesting PD-related CNVs alterations encompassed <italic>NSF</italic> and <italic>WNT3</italic> genes (later better discussed), and <italic>ATXN3</italic>, <italic>FBXW7</italic>, <italic>CHCHD3</italic>, <italic>HSF1</italic>, <italic>KLC1</italic>, and <italic>MBD3</italic>, which participate in the PD disease pathways.</p>
<p>An unusual approach was carried out by Pamphlett et al. (<xref ref-type="bibr" rid="CR113">2012</xref>), who investigated the existence of somatic candidate genetic CNVs in PD brains and missing in blood DNA. A total of 45 PD-brain-specific CNVs was found, some of which overlap with DGV regions. Candidate genes (not in controls nor in DGV) included <italic>BCL2</italic> involved in mitochondrial function and apoptosis (discussed in the following paragraphs), <italic>NRSN1</italic> implicated in cellular vesicle formation, and <italic>RYR2</italic> which participates in cellular calcium release (Supplementary Table 1). This study shows that specific brain CNVs can be detected, and raises the possibility that brain-situated mutations could underlie some cases of PD.</p>
</sec>
<sec id="Sec11">
<title>A <italic>systems biology</italic> approach for rare and singleton CNVs</title>
<p>Altogether, genome-wide studies have revealed the existence of multiple genetic loci containing rare o singleton copy number changes in PD and not reported in control cohorts (Supplementary Table 1). Although less frequent, these rare CNVs could represent potentially functional variants exerting small effects on PD pathogenesis, but not emphasized by single-gene investigations or association studies because do not reach a significant level of acceptance. These studies, in fact, are not the ideal approach for polygenic multifactorial diseases, where the pattern of allelic architecture could consist of hundreds of susceptibility loci acting together by modulating the disease itself. To overcome some of these limits, the <italic>systems biology</italic> perspective can be used to assess, in a comprehensive manner, the collective effect of these variants on PD outcome (Fig. <xref ref-type="fig" rid="Fig5">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>From a single-gene mutation perspective to a “<italic>systems biology</italic>” approach to dissect complex multifactorial diseases and improve the comprehension of the molecular basis underlying PD pathogenesis</p></caption><graphic id="MO5" xlink:href="439_2016_1749_Fig5_HTML"></graphic></fig>
</p>
<p>Interestingly, the Gene Ontologies (GO) enrichment of the total CNV-driven genes observed in PD patients until now reveals common deregulated biological processes (Fig. <xref ref-type="fig" rid="Fig6">6</xref>) mainly related to nervous system functions and morphogenesis and including brain development (<italic>p</italic> value = 2.137E<sup>−7</sup>), regulation of neurotransmission (<italic>p</italic> value = 5.465E<sup>−7</sup>), neuronal signal transduction (<italic>p</italic> value = 2.137E<sup>−6</sup>) and social behavior (<italic>p</italic> value = 3.958E<sup>−7</sup>). Moreover, several potential relationships occur between rare CNV-affected genes and the currently known Mendelian PD genes (<italic>SNCA</italic>, <italic>LRRK2</italic>, <italic>GBA</italic>, <italic>PARK2</italic>, <italic>PINK1</italic>, <italic>DJ1</italic>, <italic>VPS35, ATP13A2, PLA2G6, FBXO7, UCHL1, MAPT</italic>). As shown in Fig. <xref ref-type="fig" rid="Fig7">7</xref>, specific and meaningful associations exist (i.e., proteins jointly contribute to a shared function, but this does not necessarily mean they are physically binding each other), and some rare CNV-affected genes could represent direct or indirect targets of Mendelian genes.<fig id="Fig6"><label>Fig. 6</label><caption><p>Gene ontologies (GO) enrichment analysis of PD-specific CNV loci reveals biological processes relevant for PD pathogenesis. <bold>a</bold> Representation of the top ten most significantly enriched (FDR &lt; 0.05) canonical GO biological processes associated with candidate PD genes with copy number alterations (not reported in controls or DGV). The analysis was performed using MetaCore platform (GeneGo, Thompson Reuters). The list is arranged in descending order with the most significant biological process at the<italic> top</italic>. Detailed information about the entire list of CNVs and overlapping genes are reported in Supplementary Table 1. <italic>p</italic> values have been obtained through hypergeometric analysis and corrected by FDR (false discovery rate) method. <bold>b</bold>
<italic> Pie chart</italic> representing the percentage of genes with altered copy number in PD belonging to the top ten enriched (<italic>p</italic> &lt; 0.05) GO Biological Processes</p></caption><graphic id="MO6" xlink:href="439_2016_1749_Fig6_HTML"></graphic></fig>
<fig id="Fig7"><label>Fig. 7</label><caption><p>Potential protein–protein interactions among rare PD CNVs and the currently known Mendelian genes as shown by STRING Software v.10 (<ext-link ext-link-type="uri" xlink:href="http://string-db.org/">http://string-db.org/</ext-link>) with high confidence settings (0.700 as minimum interaction score). The <italic>legend</italic> displays the meaning of nodes and edges</p></caption><graphic id="MO7" xlink:href="439_2016_1749_Fig7_HTML"></graphic></fig>
</p>
<p>The global contribution of rare and singleton CNV-driven genes to nervous system pathophysiology and functions is also mirrored by the fact that, among those coinciding with the MIM MORBID/ORPHANET records, more than 50% are involved in syndromes with altered phenotypic nervous features, including ataxia conditions, neuropathies, dystrophies, learning and development disabilities and sensorineural disorders (Supplementary Table 2). All together, these findings support the evidence that uncommon individual CNVs may exert a susceptibility effect on PD, and strengthen the effectiveness of a <italic>systems biology</italic> approach to dissect complex multifactorial genetically heterogeneous diseases like PD.</p>
<p>Below, we will briefly discuss the GO-enriched rare genes by grouping them into three main categories (Synaptic trafficking and neurotransmission, Brain development and cell fate differentiation, Cognitive impairment). GO-enriched genes are graphically illustrated in Fig. <xref ref-type="fig" rid="Fig8">8</xref>.<fig id="Fig8"><label>Fig. 8</label><caption><p>Interaction map representing CNV-altered genes enriched in GO classes and grouped on the basis of their main biological processes. The map was created using the MetaCore Pathway Map Creator tool (GeneGo, Thompson Reuters). Detailed information about type of CNV, chromosomal size and study references are reported in Supplementary Table 1</p></caption><graphic id="MO8" xlink:href="439_2016_1749_Fig8_HTML"></graphic></fig>
</p>
<sec id="Sec12">
<title>Synaptic trafficking and neurotransmission</title>
<p>Synapses are specialized junctions of the central nervous system through which neurons connect each other to form extensive neural circuits. Synaptic functioning depends on a constant supply of energy and resources, essential for both neurotransmitters production and intracellular trafficking via repeated synaptic vesicle cycles. Alterations in synaptic stability result in a disruption of the neuronal networks, a common hallmark of several neurodegenerative conditions, including PD, Huntington’s and Alzheimer’s.</p>
<p>Along with the previously described <italic>COMT</italic>, some rare CNV-altered genes are involved in synaptic neurotransmission. One of the most interesting is the deletion of the entire <italic>TH</italic> (Tyrosine hydroxylase) gene, detected in a PD patient without evidence for dystonia but responsive to L-DOPA treatment, and in none of the controls (Supplementary Table 1) (Bademci et al. <xref ref-type="bibr" rid="CR6">2010</xref>, <xref ref-type="bibr" rid="CR7">2012</xref>). <italic>TH</italic> encodes a monooxygenase that catalyzes the conversion of <sc>l</sc>-tyrosine to L-dihydroxyphenylalanine (L-DOPA), the rate-limiting step in dopamine biosynthesis. Consistent with the essential role of TH in dopamine homeostasis, missense mutations in <italic>TH</italic> have been previously investigated, providing links with severe Parkinsonism-related phenotypes, such as Segawa’s syndrome, L-DOPA-responsive infantile Parkinsonism, or L-DOPA-responsive dystonia (DRD) in the recessive form (Bademci et al. <xref ref-type="bibr" rid="CR7">2012</xref>).</p>
<p>CNV-affected genes could alter not only dopamine metabolism but also other neurotransmitters’ signaling pathways. Convergent evidence agrees for early alterations in the cholinergic system in PD (Bohnen and Albin <xref ref-type="bibr" rid="CR10">2011</xref>; Muller and Bohnen <xref ref-type="bibr" rid="CR102">2013</xref>). In this regard, CNVs in the <italic>BChE</italic> gene, a nonspecific cholinesterase enzyme that hydrolyses many different choline-based esters, and in the synaptic choline transporter <italic>SLC5A7</italic> have been reported in some PD patients (Supplementary Table 1). Moreover, glutamate plays a central role in basal ganglia circuitry, sometimes modulated by dopamine itself. Genetic variations in the glutamate receptors <italic>GRID1,</italic> observed in some PD patients, could conceivably affect either the risk of developing PD or the phenotype.</p>
<p>
<italic>DLG1</italic>, observed deleted in a PD patient, encodes a multi-domain scaffolding protein acting in septate junction formation, signal transduction, cell proliferation and synaptogenesis. Interestingly, this gene was identified as differentially expressed in the blood of PD patients vs. controls and was suggested at high confidence as candidate biomarker for PD (Sun et al. <xref ref-type="bibr" rid="CR143">2014</xref>). Moreover, recent studies have highlighted the role of <italic>DLG1</italic> in the regulation of 5-HT2AR endocytosis and signaling (Dunn et al. <xref ref-type="bibr" rid="CR36">2014</xref>).</p>
<p>Several genes working in the synaptic vesicular cargo trafficking are affected by CNV alterations, such as <italic>SEPT5</italic> and <italic>SNAP29</italic> (both overlapping the 22q11.2 deletion), <italic>NSF, SYT15</italic>, <italic>PCLO,</italic> and <italic>KLC1</italic>. A particular focus deserves <italic>NSF</italic> (also known as <italic>N</italic>-ethylmaleimide sensitive factor), previously identified as “top-hit” in a large GWAS meta-study (rs183211) (Liu et al. <xref ref-type="bibr" rid="CR85">2011</xref>). While <italic>NSF</italic> functions in vesicular trafficking, membrane fusion, and synaptic neurotransmission are well documented, some recent studies also suggest a direct interaction between NSF and the Dopamine D1 receptor (D1R) (Chen and Liu <xref ref-type="bibr" rid="CR27">2010</xref>). This gene was also experimentally showed to be the directed target of miR-4519, a microRNA whose genetic variants are strongly associated with PD (Ghanbari et al. <xref ref-type="bibr" rid="CR46">2016</xref>).</p>
<p>An interesting deletion concerns the <italic>ADCYAP1</italic> gene, encoding the pleiotropic bioactive peptide PACAP (or pituitary adenylate cyclase-activating polypeptide). PACAP is considered a potent neurotrophic and neuroprotective factor, playing an important role during the embryonic development of the nervous system, and protecting neurons against toxic insults and neurodegeneration (Reglodi et al. <xref ref-type="bibr" rid="CR122">2011</xref>; Lee and Seo <xref ref-type="bibr" rid="CR80">2014</xref>). In the specific case of PD pathology, PACAP has been demonstrated to safeguard in vitro PD cell model against both salsolinol-induced and inflammatory-mediated toxicity (Brown et al. <xref ref-type="bibr" rid="CR15">2013</xref>, <xref ref-type="bibr" rid="CR16">2014</xref>), to protect rat dopaminergic neurons after injection of 6-OHDA into the <italic>substantia nigra</italic> (Reglodi et al. <xref ref-type="bibr" rid="CR121">2004</xref>), and to prevent Parkinson-like neuronal loss and motor deficits induced by prostaglandin J2 (Shivers et al. <xref ref-type="bibr" rid="CR132">2014</xref>).</p>
<p>Further genes founded CNV-altered and involved in synaptic functions include ion channels (<italic>KCNJ12</italic>), biochemical enzymes (<italic>NAT8L, PPP1R8</italic>) and receptors (<italic>RTN4R</italic>).</p>
</sec>
<sec id="Sec13">
<title>Brain development and cell fate determination</title>
<p>Brain development is an orchestrated, tightly regulated, and genetically programmed process with influences from the environment. Alterations in genes regulating differentiation, elaboration, and maintenance of neuronal cells can compromise neural specification events and cellular homeostasis, turning into neurodevelopmental abnormalities and neurodegenerative diseases (Mehler and Gokhan <xref ref-type="bibr" rid="CR96">2000</xref>).</p>
<p>Despite dopaminergic neurons cell death represents the leading event in PD pathology, it also physiologically occurs in developing brain during embryogenesis (van der Heide and Smidt <xref ref-type="bibr" rid="CR151">2013</xref>). The proper development of dopaminergic system requires the action of BCL2 family members, responsible for dictating cell survival or commitment to apoptosis (van der Heide and Smidt <xref ref-type="bibr" rid="CR151">2013</xref>). In this regard, a somatic deletion in <italic>BCL2</italic> has been observed in the brain of a PD patient in a homozygous state (Supplementary Table 1), likely producing deleterious effects on gene function.</p>
<p>Neuronal migration, differentiation, and death during brain development is also carefully tuned by a vast repertoire of growth and transcription factors, such as <italic>LHX1</italic> and <italic>IGF1R,</italic> observed duplicated in PD patients (Supplementary Table 1). <italic>LHX1</italic> encodes a transcription factor involved in axonal guidance and neurogenesis, and its overexpression has been demonstrated to inhibit the correct mesencephalic dopaminergic neurons differentiation (Nakatani et al. <xref ref-type="bibr" rid="CR105">2010</xref>). <italic>IGF1R</italic> produces the tyrosine kinase receptor for the IGF1 (insulin-like growth factor) signaling pathway. This pathway was found dysregulated in a previous cross-sectional transcriptomic analysis performed on PD datasets (Sutherland et al. <xref ref-type="bibr" rid="CR144">2009</xref>), and IGF1 signaling inhibitors have been proposed as promising therapies for the treatment of various late-onset neurodegenerative disorders (Cohen <xref ref-type="bibr" rid="CR32">2011</xref>). Moreover, the IGF1R reduction per se triggers protective effects in neurodegenerative conditions (Biondi et al. <xref ref-type="bibr" rid="CR9">2015</xref>), suggesting that its duplication could have a deleterious impact on neuronal life.</p>
<p>Members of the WNT family are additional factors expressed and secreted in the midbrain, involved in regulation of cell fate and patterning during embryogenesis. Among WNT family members, a singleton deletion in <italic>WNT3</italic> has been described in PD (Supplementary Table 1). <italic>WNT3</italic> is located near <italic>MAPT</italic> locus and, according to previous genome-wide association studies, variations in its genetic regions can influence the risk of developing PD (Liu et al. <xref ref-type="bibr" rid="CR85">2011</xref>; Simon-Sanchez et al. <xref ref-type="bibr" rid="CR134">2009</xref>). Moreover, the WNT/β-catenin signaling pathway is able to control the dopaminergic cell commitment in the midbrain, and is mediated by several transcription factors of TCF family (Chen <xref ref-type="bibr" rid="CR26">2013</xref>), such as <italic>TCF3</italic> observed deleted in PD (Supplementary Table 1).</p>
<p>Another interesting rare CNV-affected gene is <italic>ABL1</italic> (Supplementary Table 1), which encodes the tyrosine kinase protein c-Abl controlling neurogenesis, neurite outgrowth, and neuronal plasticity. Several lines of evidence suggest that aberrant activation of c-Abl plays an important role in PD pathogenesis: (1) c-Abl is upregulated in postmortem striatum of PD patients and its phosphorylation at Tyr412 is enhanced in substantia nigra and striatum; (2) c-Abl phosphorylates parkin and impairs its E3 ligase activity, leading to loss of dopaminergic neurons in SN; (3) c-Abl regulates the clearance of α-syn, catalyzing its phosphorylation mainly at Tyr39 and to a lesser extent at Tyr125; (4) the inhibition of c-Abl activity by several drugs (imatinib/Gleevec, nilotinib/Tasigna, bafetinib/INNO-406) protects against the loss of dopaminergic neurons in wild-type mice (Mahul-Mellier et al. <xref ref-type="bibr" rid="CR92">2014</xref>).</p>
<p>Additional CNV-altered genes, involved in brain development, neuronal migration, and synaptic plasticity, include G-coupled proteins (<italic>FPR3, PPYR1</italic>), transcription factors and coactivator (<italic>HNF1B, GRIP1</italic>), elements of ubiquitin/proteasome system (<italic>CUL5, PSMG1</italic>) and a member of the rhoGAP family (<italic>DLC1</italic>).</p>
</sec>
<sec id="Sec14">
<title>Cognitive impairment</title>
<p>The core feature of cognitive decline associated with PD is represented by an impairment of executive functions. Deficits in planning, sequencing, and execution of complex-goal-directed behavior are usually reported; working memory, episodic memory, procedural learning and attention are compromised with the presence of attentive fluctuations (Calabresi et al. <xref ref-type="bibr" rid="CR19">2006</xref>).</p>
<p>A set of rare CNV-altered genes are involved in learning, behavior and cognitive dysfunctions, including <italic>NRXN1</italic>, <italic>CNTNAP2</italic>, <italic>GRN</italic>, <italic>TBX1</italic>, <italic>GNB1L</italic> and <italic>DACH1</italic>.</p>
<p>Neurexin 1, encoded by <italic>NRXN1</italic>, is a presynaptic neuronal adhesion molecule that interacts with postsynaptic neuroligins in both glutamatergic and GABAergic synapses, and is important in synaptic specification and efficient neurotransmission. Deletions and point mutations in <italic>NRXN1</italic> are associated with a broad spectrum of neuropsychiatric and neurodevelopmental disorders, including autism, intellectual disability, epilepsy, developmental delay, and schizophrenia (Jenkins et al. <xref ref-type="bibr" rid="CR65">2014</xref>). Like <italic>NRXN1</italic>, also <italic>CNTNAP2</italic> belongs to neurexin superfamily and encodes a neuronal transmembrane protein involved in neural-glia interactions and clustering of potassium channels in myelinated axons. Variations in this gene have been involved in susceptibility to neurodevelopmental disorders and language impairment (Infante et al. <xref ref-type="bibr" rid="CR62">2015</xref>). Moreover, downregulation of <italic>CNTNAP2</italic> has been associated with AD and PD conditions (Infante et al. <xref ref-type="bibr" rid="CR62">2015</xref>; van Abel et al. <xref ref-type="bibr" rid="CR150">2012</xref>). It has been suggested that neurexins–neuroligins level fluctuations sway the balance between excitatory and inhibitory neurotransmission, leading to damage of synapses and dendrites and maybe triggering protein aggregates in neurodegenerative conditions (Sindi et al. <xref ref-type="bibr" rid="CR135">2014</xref>).</p>
<p>
<italic>GRN</italic> encodes progranulin, a multifunction protein widely distributed throughout the central nervous system primarily in neurons and microglia, and a potent autocrine neurotrophic factor and regulator of neuroinflammation (Van Kampen et al. <xref ref-type="bibr" rid="CR153">2014</xref>). Its loss-of-function mutations are known to be responsible for FTLDU-17 (ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17) and increase the risk for both Alzheimer’s and PD, suggesting important roles of progranulin in neurodegenerative processes (Chen et al. <xref ref-type="bibr" rid="CR29">2015</xref>). A deletion of <italic>GRN</italic> exons 1–11, resulting from a non-homologous recombination event, has been observed in a patient with typical GRN neuropathology, and in his sister presenting PD (Rovelet-Lecrux et al. <xref ref-type="bibr" rid="CR125">2008</xref>). Moreover, it has been recently demonstrated that progranulin gene delivery protects dopaminergic neurons in a PD model, suggesting that GRN gene therapy may have beneficial effects in the treatment of PD (Van Kampen et al. <xref ref-type="bibr" rid="CR153">2014</xref>).</p>
<p>Other CNV-driven genes include <italic>TBX1</italic> and <italic>GNB1L,</italic> both overlapping the 22q11.2 deletion, which have been associated with neuropsychiatric disorders such as schizophrenia and autism (Chen et al. <xref ref-type="bibr" rid="CR28">2012</xref>; Ishiguro et al. <xref ref-type="bibr" rid="CR63">2010</xref>; Hiramoto et al. <xref ref-type="bibr" rid="CR54">2011</xref>).</p>
</sec>
</sec>
<sec id="Sec15">
<title>Conclusions</title>
<p>A number of evidence suggests an extensive and complex genetic action of CNVs on PD etiopathogenesis. Thus far, unfortunately, only a small portion of the genetic variance has been identified; the remaining substantial components remain unknown and urgently need to be addressed. One way we can move on is using “<italic>systems biology</italic>”, a worthwhile instrument to analyze complex biological processes and generate a more definite molecular picture of PD.</p>
<p>In this review, we showed that disregarded individual rare CNVs functionally act in common deregulated biological processes relevant for PD pathogenesis and, therefore, potentially account for a portion of the “missing heritability” underlying PD. The comprehensive detection and functional characterization of rare CNVs in PD patients may be helpful to generate a more defined molecular picture of this complex disease, by revealing new candidate genes or disease-related molecular mechanisms, finally leading to improved diagnosis and counseling of mutation carriers. The forthcoming new era of genomics data promises to increase resolution and uncover new interesting clues.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec16">
<p>Below is the link to the electronic supplementary material. 
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="439_2016_1749_MOESM1_ESM.xlsx"><caption><p>Supplementary material 1 (XLSX 33 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="439_2016_1749_MOESM2_ESM.xlsx"><caption><p>Supplementary material 2 (XLSX 15 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>
<italic>ABL1</italic>
</term>
<def>
<p>ABL proto-oncogene 1, non-receptor tyrosine kinase</p>
</def>
</def-item>
<def-item>
<term>
<italic>ADCYAP1</italic>
</term>
<def>
<p>Adenylate cyclase-activating polypeptide 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>ATP13A2</italic>
</term>
<def>
<p>ATPase 13A2</p>
</def>
</def-item>
<def-item>
<term>
<italic>ATXN3</italic>
</term>
<def>
<p>Ataxin 3</p>
</def>
</def-item>
<def-item>
<term>
<italic>BCHE</italic>
</term>
<def>
<p>Butyrylcholinesterase</p>
</def>
</def-item>
<def-item>
<term>
<italic>BCL2</italic>
</term>
<def>
<p>Apoptosis regulator</p>
</def>
</def-item>
<def-item>
<term>
<italic>CHCHD3</italic>
</term>
<def>
<p>Coiled-coil-helix-coiled-coil-helix domain containing 3</p>
</def>
</def-item>
<def-item>
<term>
<italic>CNTNAP2</italic>
</term>
<def>
<p>Contactin-associated protein-like 2</p>
</def>
</def-item>
<def-item>
<term>CNVs</term>
<def>
<p>Copy number variations</p>
</def>
</def-item>
<def-item>
<term>
<italic>COMT</italic>
</term>
<def>
<p>Catechol-O-methyltransferase</p>
</def>
</def-item>
<def-item>
<term>
<italic>CUL5</italic>
</term>
<def>
<p>Cullin 5</p>
</def>
</def-item>
<def-item>
<term>D1R</term>
<def>
<p>Dopamine receptor D1</p>
</def>
</def-item>
<def-item>
<term>
<italic>DACH1</italic>
</term>
<def>
<p>Dachshund family transcription factor 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>DDOST</italic>
</term>
<def>
<p>Dolichyl-diphosphooligosaccharide–protein glycosyltransferase non-catalytic subunit</p>
</def>
</def-item>
<def-item>
<term>
<italic>DGCR8</italic>
</term>
<def>
<p>DGCR8 microprocessor complex subunit</p>
</def>
</def-item>
<def-item>
<term>
<italic>DLC1</italic>
</term>
<def>
<p>DLC1 Rho GTPase-activating protein</p>
</def>
</def-item>
<def-item>
<term>
<italic>DLG1</italic>
</term>
<def>
<p>Discs large MAGUK scaffold protein 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>DOCK5</italic>
</term>
<def>
<p>Dedicator of cytokinesis 5</p>
</def>
</def-item>
<def-item>
<term>
<italic>FBXO7</italic>
</term>
<def>
<p>F-box protein 7</p>
</def>
</def-item>
<def-item>
<term>
<italic>FBXW7</italic>
</term>
<def>
<p>F-box and WD repeat domain containing 7</p>
</def>
</def-item>
<def-item>
<term>FISH</term>
<def>
<p>Fluorescent in situ hybridization</p>
</def>
</def-item>
<def-item>
<term>
<italic>FoSTeS</italic>
</term>
<def>
<p>Fork stalling and template switching</p>
</def>
</def-item>
<def-item>
<term>
<italic>FPR3</italic>
</term>
<def>
<p>Formyl peptide receptor 3</p>
</def>
</def-item>
<def-item>
<term>FTLDU-17</term>
<def>
<p>Ubiquitin-positive frontotemporal lobar degeneration linked to chromosome 17</p>
</def>
</def-item>
<def-item>
<term>
<italic>GAK-DGKQ</italic>
</term>
<def>
<p>Cyclin G-associated kinase-diacylglycerol kinase theta</p>
</def>
</def-item>
<def-item>
<term>
<italic>GBA</italic>
</term>
<def>
<p>Glucosylceramidase beta</p>
</def>
</def-item>
<def-item>
<term>
<italic>GBAP1</italic>
</term>
<def>
<p>Glucosylceramidase beta pseudogene 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>GNB1L</italic>
</term>
<def>
<p>G protein subunit beta 1 like</p>
</def>
</def-item>
<def-item>
<term>
<italic>GRID1</italic>
</term>
<def>
<p>Glutamate ionotropic receptor delta type subunit 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>GRIP1</italic>
</term>
<def>
<p>Glutamate receptor interacting protein 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>GRN</italic>
</term>
<def>
<p>Granulin</p>
</def>
</def-item>
<def-item>
<term>
<italic>HNF1B</italic>
</term>
<def>
<p>HNF1 homeobox B</p>
</def>
</def-item>
<def-item>
<term>
<italic>HSF1</italic>
</term>
<def>
<p>Heat-shock transcription factor 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>HTRA2</italic>
</term>
<def>
<p>HtrA serine peptidase 2</p>
</def>
</def-item>
<def-item>
<term>IGF1</term>
<def>
<p>Insulin growth factor 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>IGF1R</italic>
</term>
<def>
<p>Insulin-like growth factor 1 receptor</p>
</def>
</def-item>
<def-item>
<term>
<italic>KCNJ12</italic>
</term>
<def>
<p>Potassium voltage-gated channel subfamily J member 12</p>
</def>
</def-item>
<def-item>
<term>
<italic>KLC1</italic>
</term>
<def>
<p>Kinesin light chain 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>LHX1</italic>
</term>
<def>
<p>LIM homeobox 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>LRRK2</italic>
</term>
<def>
<p>Leucine-rich repeat kinase 2</p>
</def>
</def-item>
<def-item>
<term>
<italic>MAPT</italic>
</term>
<def>
<p>Microtubule-associated protein tau</p>
</def>
</def-item>
<def-item>
<term>
<italic>MBD3</italic>
</term>
<def>
<p>Methyl–CpG binding domain protein 3</p>
</def>
</def-item>
<def-item>
<term>NAHR</term>
<def>
<p>Non-allelic homologous recombination</p>
</def>
</def-item>
<def-item>
<term>
<italic>NAT8L</italic>
</term>
<def>
<p>
<italic>N</italic>-Acetyltransferase 8 like</p>
</def>
</def-item>
<def-item>
<term>
<italic>NHEJ</italic>
</term>
<def>
<p>Non-homologous end joining</p>
</def>
</def-item>
<def-item>
<term>
<italic>NRSN1</italic>
</term>
<def>
<p>Neurensin 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>NRXN1</italic>
</term>
<def>
<p>Neurexin 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>NSF</italic>
</term>
<def>
<p>
<italic>N</italic>-Ethylmaleimide-sensitive factor, vesicle fusing ATPase</p>
</def>
</def-item>
<def-item>
<term>
<italic>OVOS2</italic>
</term>
<def>
<p>Ovostatin 2</p>
</def>
</def-item>
<def-item>
<term>PACAP</term>
<def>
<p>Pituitary adenylate cyclase-activating polypeptide</p>
</def>
</def-item>
<def-item>
<term>
<italic>PARK10</italic>
</term>
<def>
<p>Parkinson disease 10</p>
</def>
</def-item>
<def-item>
<term>
<italic>PARK12</italic>
</term>
<def>
<p>Parkinson disease 12</p>
</def>
</def-item>
<def-item>
<term>
<italic>PARK16</italic>
</term>
<def>
<p>Parkinson disease 16</p>
</def>
</def-item>
<def-item>
<term>
<italic>PARK2</italic>
</term>
<def>
<p>Parkin RBR E3 ubiquitin protein ligase</p>
</def>
</def-item>
<def-item>
<term>
<italic>PARK3</italic>
</term>
<def>
<p>Parkinson disease 3 (autosomal dominant, Lewy body)</p>
</def>
</def-item>
<def-item>
<term>
<italic>PARK7</italic>
</term>
<def>
<p>Parkinsonism-associated deglycase</p>
</def>
</def-item>
<def-item>
<term>
<italic>PCLO</italic>
</term>
<def>
<p>Piccolo presynaptic cytomatrix protein</p>
</def>
</def-item>
<def-item>
<term>
<italic>PINK1</italic>
</term>
<def>
<p>PTEN-induced putative kinase 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>PLA2G6</italic>
</term>
<def>
<p>Phospholipase A2 group VI</p>
</def>
</def-item>
<def-item>
<term>
<italic>PPP1R8</italic>
</term>
<def>
<p>Protein phosphatase 1 regulatory subunit 8</p>
</def>
</def-item>
<def-item>
<term>
<italic>PPYR1</italic>
</term>
<def>
<p>Neuropeptide Y receptor Y4</p>
</def>
</def-item>
<def-item>
<term>
<italic>PSMG1</italic>
</term>
<def>
<p>Proteasome assembly chaperone 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>RTN4R</italic>
</term>
<def>
<p>Reticulon 4 receptor</p>
</def>
</def-item>
<def-item>
<term>
<italic>RYR2</italic>
</term>
<def>
<p>Ryanodine receptor 2</p>
</def>
</def-item>
<def-item>
<term>
<italic>SEPT5</italic>
</term>
<def>
<p>Septin 5</p>
</def>
</def-item>
<def-item>
<term>
<italic>SLC5A7</italic>
</term>
<def>
<p>Solute carrier family 5 member 7</p>
</def>
</def-item>
<def-item>
<term>
<italic>SNAP29</italic>
</term>
<def>
<p>Synaptosome-associated protein 29</p>
</def>
</def-item>
<def-item>
<term>
<italic>SNCA</italic>
</term>
<def>
<p>Alpha-synuclein</p>
</def>
</def-item>
<def-item>
<term>
<italic>SYNJ1</italic>
</term>
<def>
<p>Synaptojanin 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>SYT15</italic>
</term>
<def>
<p>Synaptotagmin 15</p>
</def>
</def-item>
<def-item>
<term>
<italic>TBX1</italic>
</term>
<def>
<p>T-box 1</p>
</def>
</def-item>
<def-item>
<term>
<italic>TCF3</italic>
</term>
<def>
<p>Transcription factor 3</p>
</def>
</def-item>
<def-item>
<term>
<italic>TH</italic>
</term>
<def>
<p>Tyrosine hydroxylase</p>
</def>
</def-item>
<def-item>
<term>
<italic>UCHL1</italic>
</term>
<def>
<p>Ubiquitin C-terminal hydrolase L1</p>
</def>
</def-item>
<def-item>
<term>UPS</term>
<def>
<p>Ubiquitin proteasome system</p>
</def>
</def-item>
<def-item>
<term>
<italic>USP32</italic>
</term>
<def>
<p>Ubiquitin-specific peptidase 32</p>
</def>
</def-item>
<def-item>
<term>
<italic>VPS35</italic>
</term>
<def>
<p>VPS35 retromer complex component</p>
</def>
</def-item>
<def-item>
<term>
<italic>WNT3</italic>
</term>
<def>
<p>Wnt family member 3</p>
</def>
</def-item>
<def-item>
<term>5-HT2AR</term>
<def>
<p>Serotonin 2A receptor</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by the Italian Ministry of Education, Universities and Research through grant CTN01_00177_817708 and the international Ph.D. program in Neuroscience of the University of Catania. Authors gratefully acknowledge Cristina Calì, Alfia Corsino, Maria Patrizia D’Angelo and Francesco Marino for their administrative and technical support.</p>
</ack>
<notes notes-type="COI-statement">
<title>Compliance with ethical standards</title>
<sec id="FPar1">
<title>Conflict of interest</title>
<p>On behalf of all authors, the corresponding author states that there is no conflict of interest.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>α-Synuclein gene duplication is present in sporadic Parkinson disease</article-title>
<source/>Neurology
          <year>2008</year>
<volume>70</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000271080.53272.c7</pub-id>
<pub-id pub-id-type="pmid">17625105</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Mubarak</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Bohlega</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Alkhairallah</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Magrashi</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>AlTurki</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Khalil</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>AlAbdulaziz</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Abou Al-Shaar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mustafa</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Alyemni</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Alsaffar</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Tahir</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Al Tassan</surname>
<given-names>NA</given-names>
</name>
</person-group>
<article-title>Parkinson’s Disease in Saudi Patients: a Genetic Study</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<issue>8</issue>
<fpage>e0135950</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0135950</pub-id>
<pub-id pub-id-type="pmid">26274610</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambroziak</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Koziorowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Duszyc</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gorka-Skoczylas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Potulska-Chromik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Slawek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoffman-Zacharska</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Genomic instability in the PARK2 locus is associated with Parkinson’s disease</article-title>
<source/>J Appl Genet
          <year>2015</year>
<volume>56</volume>
<issue>4</issue>
<fpage>451</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1007/s13353-015-0282-9</pub-id>
<pub-id pub-id-type="pmid">25833766</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariga</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takahashi-Niki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Niki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iguchi-Ariga</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Neuroprotective function of DJ-1 in Parkinson’s disease</article-title>
<source/>Oxid Med Cell Longev
          <year>2013</year>
<volume>2013</volume>
<fpage>683920</fpage>
<pub-id pub-id-type="doi">10.1155/2013/683920</pub-id>
<pub-id pub-id-type="pmid">23766857</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atsumi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tomiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>[A 62-year-old woman with early-onset Parkinson’s disease associated with the PINKi gene deletion]</article-title>
<source/>Rinsho shinkeigaku Clin Neurol
          <year>2006</year>
<volume>46</volume>
<issue>3</issue>
<fpage>199</fpage>
<lpage>202</lpage>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bademci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Zuchner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease</article-title>
<source/>Hum Mutat
          <year>2010</year>
<volume>31</volume>
<issue>10</issue>
<fpage>E1767</fpage>
<lpage>E1771</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21351</pub-id>
<pub-id pub-id-type="pmid">20809526</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bademci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson’s disease</article-title>
<source/>CNS Neurol Disord Drug Targets
          <year>2012</year>
<volume>11</volume>
<issue>4</issue>
<fpage>469</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.2174/187152712800792866</pub-id>
<pub-id pub-id-type="pmid">22583432</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betarbet</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sherer</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Greenamyre</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Ubiquitin-proteasome system and Parkinson’s diseases</article-title>
<source/>Exp Neurol
          <year>2005</year>
<volume>191</volume>
<issue>Suppl 1</issue>
<fpage>S17</fpage>
<lpage>S27</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2004.08.021</pub-id>
<pub-id pub-id-type="pmid">15629758</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biondi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Branchu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ben Salah</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Houdebine</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bertin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chali</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Desseille</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Weill</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lancelin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aid</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pariset</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lecolle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cote</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Holzenberger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chanoine</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Massaad</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Charbonnier</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>IGF-1R reduction triggers neuroprotective signaling pathways in spinal muscular atrophy mice</article-title>
<source/>J Neurosci Off J Soc Neurosci
          <year>2015</year>
<volume>35</volume>
<issue>34</issue>
<fpage>12063</fpage>
<lpage>12079</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0608-15.2015</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohnen</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Albin</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>The cholinergic system and Parkinson disease</article-title>
<source/>Behav Brain Res
          <year>2011</year>
<volume>221</volume>
<issue>2</issue>
<fpage>564</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2009.12.048</pub-id>
<pub-id pub-id-type="pmid">20060022</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Autosomal recessive parkinsonism</article-title>
<source/>Parkinsonism Relat Disord
          <year>2012</year>
<volume>18</volume>
<issue>Suppl 1</issue>
<fpage>S4</fpage>
<lpage>S6</lpage>
<pub-id pub-id-type="doi">10.1016/S1353-8020(11)70004-9</pub-id>
<pub-id pub-id-type="pmid">22166450</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Genetics of Parkinson’s disease—state of the art, 2013</article-title>
<source/>Parkinsonism Relat Disord
          <year>2014</year>
<volume>20</volume>
<issue>Suppl 1</issue>
<fpage>S23</fpage>
<lpage>S28</lpage>
<pub-id pub-id-type="doi">10.1016/S1353-8020(13)70009-9</pub-id>
<pub-id pub-id-type="pmid">24262182</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rizzu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Squitieri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Krieger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vanacore</surname>
<given-names>N</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Duijn</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Oostra</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Meco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Heutink</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism</article-title>
<source/>Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol
          <year>2003</year>
<volume>24</volume>
<issue>3</issue>
<fpage>159</fpage>
<lpage>160</lpage>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Booij</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Amelsvoort</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boot</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: potential role for dopamine transporter imaging</article-title>
<source/>Am J Med Genet Part A
          <year>2010</year>
<volume>152A</volume>
<issue>11</issue>
<fpage>2937</fpage>
<lpage>2938</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33665</pub-id>
<pub-id pub-id-type="pmid">20949509</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tamas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reglodi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tizabi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson’s disease</article-title>
<source/>J Mol Neurosci MN
          <year>2013</year>
<volume>50</volume>
<issue>3</issue>
<fpage>600</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-013-0015-7</pub-id>
<pub-id pub-id-type="pmid">23625270</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tamas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reglodi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tizabi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson’s disease</article-title>
<source/>Neurotox Res
          <year>2014</year>
<volume>26</volume>
<issue>3</issue>
<fpage>230</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-014-9468-x</pub-id>
<pub-id pub-id-type="pmid">24740430</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<mixed-citation publication-type="other">Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, Lohmann K, Klein C, Djarmati A (2008) Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 71(16):1294; author reply 1294. doi:10.1212/01.wnl.0000338439.00992.c7</mixed-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Kiehl</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Hazrati</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Rogaeva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications</article-title>
<source/>JAMA Neurol
          <year>2013</year>
<volume>70</volume>
<issue>11</issue>
<fpage>1359</fpage>
<lpage>1366</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2013.3646</pub-id>
<pub-id pub-id-type="pmid">24018986</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabresi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Picconi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Parnetti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di Filippo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine-acetylcholine synaptic balance</article-title>
<source/>Lancet Neurol
          <year>2006</year>
<volume>5</volume>
<issue>11</issue>
<fpage>974</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(06)70600-7</pub-id>
<pub-id pub-id-type="pmid">17052664</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camargos</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Dornas</surname>
<given-names>LO</given-names>
</name>
<name>
<surname>Momeni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Familial Parkinsonism and early onset Parkinson’s disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2009</year>
<volume>24</volume>
<issue>5</issue>
<fpage>662</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1002/mds.22365</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantsilieris</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>White</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Molecular methods for genotyping complex copy number polymorphisms</article-title>
<source/>Genomics
          <year>2013</year>
<volume>101</volume>
<issue>2</issue>
<fpage>86</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygeno.2012.10.004</pub-id>
<pub-id pub-id-type="pmid">23123317</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carter</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Fiegler</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Piper</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Comparative analysis of comparative genomic hybridization microarray technologies: report of a workshop sponsored by the Wellcome Trust</article-title>
<source/>Cytometry
          <year>2002</year>
<volume>49</volume>
<issue>2</issue>
<fpage>43</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1002/cyto.10153</pub-id>
<pub-id pub-id-type="pmid">12357458</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cazeneuve</surname>
<given-names>C</given-names>
</name>
<name>
<surname>San</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mukhtar</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Kheir</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Leguern</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Salih</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson’s disease</article-title>
<source/>Neurogenetics
          <year>2009</year>
<volume>10</volume>
<issue>3</issue>
<fpage>265</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-009-0174-4</pub-id>
<pub-id pub-id-type="pmid">19214605</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chartier-Harlin</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Roumier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mouroux</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Douay</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Levecque</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Larvor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andrieux</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hulihan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Waucquier</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Defebvre</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Amouyel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Destee</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>α-Synuclein locus duplication as a cause of familial Parkinson’s Dis</article-title>
<source/>Lancet
          <year>2004</year>
<volume>364</volume>
<issue>9440</issue>
<fpage>1167</fpage>
<lpage>1169</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(04)17103-1</pub-id>
<pub-id pub-id-type="pmid">15451224</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhary</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Behari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dihana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Swaminath</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Govindappa</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Jayaram</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Maitra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muthane</surname>
<given-names>UB</given-names>
</name>
<name>
<surname>Juyal</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Thelma</surname>
<given-names>BK</given-names>
</name>
</person-group>
<article-title>Parkin mutations in familial and sporadic Parkinson’s disease among Indians</article-title>
<source/>Parkinsonism Relat Disord
          <year>2006</year>
<volume>12</volume>
<issue>4</issue>
<fpage>239</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2005.12.004</pub-id>
<pub-id pub-id-type="pmid">16500134</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<mixed-citation publication-type="other">Chen L-W (2013) Roles of Wnt/β-catenin signaling in controlling the dopaminergic neuronal cell commitment of midbrain and therapeutic application for Parkinson’s disease. In: Wislet-Gendebien S (ed) Trends in cell signaling pathways in neuronal fate decision. InTech. doi:10.5772/53282</mixed-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Interaction of dopamine D1 receptor with <italic>N</italic>-ethylmaleimide-sensitive factor is important for the membrane localization of the receptor</article-title>
<source/>J Neurosci Res
          <year>2010</year>
<volume>88</volume>
<issue>11</issue>
<fpage>2504</fpage>
<lpage>2512</lpage>
<pub-id pub-id-type="pmid">20623535</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>YZ</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lisowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sul</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bernier</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Estes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Minshew</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shellenberg</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Rieder</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nickerson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Tsuang</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Wijsman</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Raskind</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Brkanac</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Evidence for involvement of GNB1L in autism</article-title>
<source/>Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet
          <year>2012</year>
<volume>159B</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32002</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis</article-title>
<source/>J Neurol
          <year>2015</year>
<volume>262</volume>
<issue>4</issue>
<fpage>814</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-014-7630-2</pub-id>
<pub-id pub-id-type="pmid">25578179</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Lyoo</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Baik</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YJ</given-names>
</name>
</person-group>
<article-title>Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease</article-title>
<source/>Neurogenetics
          <year>2008</year>
<volume>9</volume>
<issue>4</issue>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-008-0138-0</pub-id>
<pub-id pub-id-type="pmid">18704525</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YJ</given-names>
</name>
</person-group>
<article-title>Analysis of dosage mutation in PARK2 among Korean patients with early-onset or familial Parkinson’s disease</article-title>
<source/>J Clin Neurol
          <year>2014</year>
<volume>10</volume>
<issue>3</issue>
<fpage>244</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.3988/jcn.2014.10.3.244</pub-id>
<pub-id pub-id-type="pmid">25045378</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Countering neurodegeneration by reducing the activity of the insulin/IGF signaling pathway: current knowledge and future prospects</article-title>
<source/>Exp Gerontol
          <year>2011</year>
<volume>46</volume>
<issue>2–3</issue>
<fpage>124</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2010.08.032</pub-id>
<pub-id pub-id-type="pmid">20849948</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darvish</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Movafagh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Omrani</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Firouzabadi</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Azargashb</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jamshidi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Khaligh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haghnejad</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Naeini</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Talebi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heidari-Rostami</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Noorollahi-Moghaddam</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Karkheiran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shahidi</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Paknejad</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ashrafian</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abdi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kayyal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akbari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pedram</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Emamalizadeh</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Detection of copy number changes in genes associated with Parkinson’s disease in Iranian patients</article-title>
<source/>Neurosci Lett
          <year>2013</year>
<volume>551</volume>
<fpage>75</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2013.07.013</pub-id>
<pub-id pub-id-type="pmid">23880019</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Junn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mouradian</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>The role of oxidative stress in Parkinson’s disease</article-title>
<source/>J Parkinson’s Dis
          <year>2013</year>
<volume>3</volume>
<issue>4</issue>
<fpage>461</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="pmid">24252804</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djarmati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hedrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Svetel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Juric</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vukosavic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Romac</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kostic</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: parkin mutation frequency depends on ethnic origin of patients</article-title>
<source/>Hum Mutat
          <year>2004</year>
<volume>23</volume>
<issue>5</issue>
<fpage>525</fpage>
<pub-id pub-id-type="doi">10.1002/humu.9240</pub-id>
<pub-id pub-id-type="pmid">15108293</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunn</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Caetano</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Godin</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Role of SAP97 in the regulation of 5-HT2AR endocytosis and signaling</article-title>
<source/>Mol Pharmacol
          <year>2014</year>
<volume>86</volume>
<issue>3</issue>
<fpage>275</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1124/mol.114.093476</pub-id>
<pub-id pub-id-type="pmid">24989932</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elfferich</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Verleun-Mooijman</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Maat-Kievit</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>van de Warrenburg</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Abdo</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Eshuis</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Leenders</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Hovestadt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zijlmans</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Stroy</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Boon</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>van Engelen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Verschuuren-Bemelmans</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Lesnik-Oberstein</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Tassorelli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lopiano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dooijes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Minkelen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations</article-title>
<source/>Neurogenetics
          <year>2011</year>
<volume>12</volume>
<issue>4</issue>
<fpage>263</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-011-0302-9</pub-id>
<pub-id pub-id-type="pmid">21993715</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elia</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Petrucci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valbonesi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Consoli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ferraris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2013</year>
<volume>28</volume>
<issue>6</issue>
<fpage>813</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25518</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Forno</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gwinn-Hardy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hussey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tanner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Langston</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Lewy bodies and parkinsonism in families with parkin mutations</article-title>
<source/>Ann Neurol
          <year>2001</year>
<volume>50</volume>
<issue>3</issue>
<fpage>293</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1002/ana.1132</pub-id>
<pub-id pub-id-type="pmid">11558785</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Forno</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Hulihan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maraganore</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gwinn-Hardy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Langston</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications</article-title>
<source/>Ann Neurol
          <year>2004</year>
<volume>55</volume>
<issue>2</issue>
<fpage>174</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1002/ana.10846</pub-id>
<pub-id pub-id-type="pmid">14755720</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferese</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Modugno</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Campopiano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Santilli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zampatti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giardina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nardone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Postorivo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fornai</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Novelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Romoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ruggieri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gambardella</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Four copies of SNCA responsible for autosomal dominant Parkinson’s Disease in two Italian siblings</article-title>
<source/>Parkinson’s Dis
          <year>2015</year>
<volume>2015</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1155/2015/546462</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Andrey</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schwarzer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Heinrich</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schopflin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kempfer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jerkovic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Spielmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Timmermann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wittler</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cambiaso</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zuffardi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Houge</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lambie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brancati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pombo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vingron</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spitz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mundlos</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Formation of new chromatin domains determines pathogenicity of genomic duplications</article-title>
<source/>Nature
          <year>2016</year>
<volume>538</volume>
<issue>7624</issue>
<fpage>265</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1038/nature19800</pub-id>
<pub-id pub-id-type="pmid">27706140</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Munz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Schule</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Langston</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Hulihan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication</article-title>
<source/>Neurology
          <year>2007</year>
<volume>68</volume>
<issue>12</issue>
<fpage>916</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000254458.17630.c5</pub-id>
<pub-id pub-id-type="pmid">17251522</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamazon</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Stranger</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>The impact of human copy number variation on gene expression</article-title>
<source/>Brief Funct Genom
          <year>2015</year>
<volume>14</volume>
<issue>5</issue>
<fpage>352</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1093/bfgp/elv017</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garraux</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Caberg</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Vanbellinghen</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Jamar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bours</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Moonen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dive</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Partial trisomy 4q associated with young-onset dopa-responsive parkinsonism</article-title>
<source/>Arch Neurol
          <year>2012</year>
<volume>69</volume>
<issue>3</issue>
<fpage>398</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1001/archneurol.2011.802</pub-id>
<pub-id pub-id-type="pmid">22410449</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanbari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Darweesh</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>de Looper</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>van Luijn</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ikram</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Erkeland</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Dehghan</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genetic Variants in MicroRNAs and Their Binding Sites Are Associated with the Risk of Parkinson Disease</article-title>
<source/>Hum Mutat
          <year>2016</year>
<volume>37</volume>
<issue>3</issue>
<fpage>292</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22943</pub-id>
<pub-id pub-id-type="pmid">26670097</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grayton</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Copy number variations in neurodevelopmental disorders</article-title>
<source/>Prog Neurobiol
          <year>2012</year>
<volume>99</volume>
<issue>1</issue>
<fpage>81</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2012.07.005</pub-id>
<pub-id pub-id-type="pmid">22813947</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lupski</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>CNV and nervous system diseases—what’s new?</article-title>
<source/>Cytogenet Genome Res
          <year>2008</year>
<volume>123</volume>
<issue>1–4</issue>
<fpage>54</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">19287139</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerrero Camacho</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Monroy Jaramillo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yescas Gomez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rodriguez Violante</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boll Woehrlen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alonso Vilatela</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Lopez Lopez</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson’s disease</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2012</year>
<volume>27</volume>
<issue>8</issue>
<fpage>1047</fpage>
<lpage>1051</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25030</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XW</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>XX</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism</article-title>
<source/>J Neurol
          <year>2010</year>
<volume>257</volume>
<issue>7</issue>
<fpage>1170</fpage>
<lpage>1175</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-010-5485-8</pub-id>
<pub-id pub-id-type="pmid">20146068</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>XX</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Exon dosage analysis of parkin gene in Chinese sporadic Parkinson’s disease</article-title>
<source/>Neurosci Lett
          <year>2015</year>
<volume>604</volume>
<fpage>47</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2015.07.046</pub-id>
<pub-id pub-id-type="pmid">26240990</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Djarmati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wellenbrock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Hilker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vieregge</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ozelius</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Heutink</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schwinger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Noth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bressman</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Pramstaller</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease</article-title>
<source/>Neurology
          <year>2004</year>
<volume>62</volume>
<issue>3</issue>
<fpage>389</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000113022.51739.88</pub-id>
<pub-id pub-id-type="pmid">14872018</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hehir-Kwa</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Veltman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>de Leeuw</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Pathogenic or not? Assessing the clinical relevance of copy number variants</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>84</volume>
<issue>5</issue>
<fpage>415</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12242</pub-id>
<pub-id pub-id-type="pmid">23895381</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiramoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kucherlapati</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hiroi</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Tbx1: identification of a 22q11.2 gene as a risk factor for autism spectrum disorder in a mouse model</article-title>
<source/>Hum Mol Genet
          <year>2011</year>
<volume>20</volume>
<issue>24</issue>
<fpage>4775</fpage>
<lpage>4785</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddr404</pub-id>
<pub-id pub-id-type="pmid">21908517</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoyer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Braathen</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Eek</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Nordang</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Skjelbred</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>MB</given-names>
</name>
</person-group>
<article-title>Copy number variations in a population-based study of Charcot-Marie-Tooth disease</article-title>
<source/>BioMed research international
          <year>2015</year>
<volume>2015</volume>
<fpage>960404</fpage>
<pub-id pub-id-type="pmid">25648254</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huttenlocher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Helgadottir</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Sveinbjornsdottir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stefansson</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson’s disease</article-title>
<source/>Hum Mol Genet
          <year>2015</year>
<volume>24</volume>
<issue>19</issue>
<fpage>5637</fpage>
<lpage>5643</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv277</pub-id>
<pub-id pub-id-type="pmid">26188007</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iafrate</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Feuk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Listewnik</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Donahoe</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Detection of large-scale variation in the human genome</article-title>
<source/>Nat Genet
          <year>2004</year>
<volume>36</volume>
<issue>9</issue>
<fpage>949</fpage>
<lpage>951</lpage>
<pub-id pub-id-type="doi">10.1038/ng1416</pub-id>
<pub-id pub-id-type="pmid">15286789</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibanez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Debarges</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tison</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease</article-title>
<source/>Lancet
          <year>2004</year>
<volume>364</volume>
<issue>9440</issue>
<fpage>1169</fpage>
<lpage>1171</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(04)17104-3</pub-id>
<pub-id pub-id-type="pmid">15451225</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibanez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lesage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Janin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Durif</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Destee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Brefel-Courbon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zelenika</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<collab>French Parkinson’s Disease Genetics Study G </collab>
</person-group>
<article-title>Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms</article-title>
<source/>Arch Neurol
          <year>2009</year>
<volume>66</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1001/archneurol.2008.555</pub-id>
<pub-id pub-id-type="pmid">19139307</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikeuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kakita</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shiga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kasuga</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Idezuka</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Onodera</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Iwatsubo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishizawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia</article-title>
<source/>Arch Neurol
          <year>2008</year>
<volume>65</volume>
<issue>4</issue>
<fpage>514</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.65.4.514</pub-id>
<pub-id pub-id-type="pmid">18413475</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inazawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Imoto</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes</article-title>
<source/>Cancer Sci
          <year>2004</year>
<volume>95</volume>
<issue>7</issue>
<fpage>559</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb02486.x</pub-id>
<pub-id pub-id-type="pmid">15245590</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Infante</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sierra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez-Juan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gonzalez-Aramburu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sanchez-Quintana</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Berciano</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Combarros</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sainz</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Identification of candidate genes for Parkinson’s disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls</article-title>
<source/>Neurobiol Aging
          <year>2015</year>
<volume>36</volume>
<issue>2</issue>
<fpage>1105</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.10.039</pub-id>
<pub-id pub-id-type="pmid">25475535</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishiguro</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Morikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niizato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Iritani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Itokawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ujike</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kunugi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Someya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kakita</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arinami</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Supportive evidence for reduced expression of GNB1L in schizophrenia</article-title>
<source/>Schizophr Bull
          <year>2010</year>
<volume>36</volume>
<issue>4</issue>
<fpage>756</fpage>
<lpage>765</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbn160</pub-id>
<pub-id pub-id-type="pmid">19011233</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishkanian</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Malloff</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>DeLeeuw</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Snijders</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albertson</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Pinkel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>V</given-names>
</name>
<name>
<surname>MacAulay</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>A tiling resolution DNA microarray with complete coverage of the human genome</article-title>
<source/>Nat Genet
          <year>2004</year>
<volume>36</volume>
<issue>3</issue>
<fpage>299</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1038/ng1307</pub-id>
<pub-id pub-id-type="pmid">14981516</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenkins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Apud</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Decot</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia</article-title>
<source/>Neuropsychopharmacol Off Publ Am College Neuropsychopharmacol
          <year>2014</year>
<volume>39</volume>
<issue>9</issue>
<fpage>2170</fpage>
<lpage>2178</lpage>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Structural chromosomal variations in neurological diseases</article-title>
<source/>Neurologist
          <year>2009</year>
<volume>15</volume>
<issue>5</issue>
<fpage>245</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1097/NRL.0b013e3181963cef</pub-id>
<pub-id pub-id-type="pmid">19741431</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kara</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kiely</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Proukakis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Giffin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hehir</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rantell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pandraud</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Nacheva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pittman</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A 6.4 Mb duplication of the alpha-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations</article-title>
<source/>JAMA Neurol
          <year>2014</year>
<volume>71</volume>
<issue>9</issue>
<fpage>1162</fpage>
<lpage>1171</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2014.994</pub-id>
<pub-id pub-id-type="pmid">25003242</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Hamza</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Montimurro</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Zabetian</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Factor</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Samii</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Molho</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Gancher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moses</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zareparsi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Poorkaj</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nutt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schellenberg</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Payami</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2</article-title>
<source/>Neurology
          <year>2010</year>
<volume>75</volume>
<issue>13</issue>
<fpage>1189</fpage>
<lpage>1194</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f4d832</pub-id>
<pub-id pub-id-type="pmid">20876472</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keyser</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lombard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Veikondis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bardien</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Analysis of exon dosage using MLPA in South African Parkinson’s disease patients</article-title>
<source/>Neurogenetics
          <year>2010</year>
<volume>11</volume>
<issue>3</issue>
<fpage>305</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-009-0229-6</pub-id>
<pub-id pub-id-type="pmid">20013014</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Seong</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease</article-title>
<source/>Clin Genet
          <year>2012</year>
<volume>82</volume>
<issue>1</issue>
<fpage>77</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01693.x</pub-id>
<pub-id pub-id-type="pmid">21534944</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Westenberger</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genetics of Parkinson’s disease</article-title>
<source/>Cold Spring Harbor Perspect Med
          <year>2012</year>
<volume>2</volume>
<issue>1</issue>
<fpage>a008888</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a008888</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pramstaller</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Kis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Page</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Kann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Woodward</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Castellan</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vieregge</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Breakefield</surname>
<given-names>XO</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Ozelius</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype</article-title>
<source/>Ann Neurol
          <year>2000</year>
<volume>48</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1002/1531-8249(200007)48:1&lt;65::AID-ANA10&gt;3.0.CO;2-L</pub-id>
<pub-id pub-id-type="pmid">10894217</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Djarmati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hedrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Scaglione</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Marchese</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kock</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schule</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hiller</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lohnau</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wiegers</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Abbruzzese</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pramstaller</surname>
<given-names>PP</given-names>
</name>
</person-group>
<article-title>PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism</article-title>
<source/>Eur J Human Genet EJHG
          <year>2005</year>
<volume>13</volume>
<issue>9</issue>
<fpage>1086</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201455</pub-id>
<pub-id pub-id-type="pmid">15970950</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kojovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sheerin</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Rubio-Agusti</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bras</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Young-onset parkinsonism due to homozygous duplication of α-synuclein in a consanguineous family</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2012</year>
<volume>27</volume>
<issue>14</issue>
<fpage>1827</fpage>
<lpage>1829</lpage>
<pub-id pub-id-type="doi">10.1002/mds.25199</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Puschmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>ZK</given-names>
</name>
</person-group>
<article-title>Autosomal dominant Parkinson’s disease caused by SNCA duplications</article-title>
<source/>Parkinsonism Relat Disord
          <year>2016</year>
<volume>22</volume>
<issue>Suppl 1</issue>
<fpage>S1</fpage>
<lpage>S6</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.09.007</pub-id>
<pub-id pub-id-type="pmid">26350119</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krahn</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Maraganore</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Michels</surname>
<given-names>VV</given-names>
</name>
</person-group>
<article-title>Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22</article-title>
<source/>Mayo Clin Proc
          <year>1998</year>
<volume>73</volume>
<issue>10</issue>
<fpage>956</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.4065/73.10.956</pub-id>
<pub-id pub-id-type="pmid">9787744</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Cognata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Iemmolo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>D’Agata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Scuderi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Drago</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zappia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Increasing the coding potential of genomes through alternative splicing: the case of PARK2 Gene</article-title>
<source/>Curr Genom
          <year>2014</year>
<volume>15</volume>
<issue>3</issue>
<fpage>203</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="doi">10.2174/1389202915666140426003342</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>La Cognata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>D’Agata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cavalcanti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Parkin Alternative Splicing: Not only Parkinsonism</article-title>
<source/>ARC J Neurosci
          <year>2016</year>
<volume>1</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>18</lpage>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lupski</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders</article-title>
<source/>Neuron
          <year>2006</year>
<volume>52</volume>
<issue>1</issue>
<fpage>103</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2006.09.027</pub-id>
<pub-id pub-id-type="pmid">17015230</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases</article-title>
<source/>BMB Rep
          <year>2014</year>
<volume>47</volume>
<issue>7</issue>
<fpage>369</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.5483/BMBRep.2014.47.7.086</pub-id>
<pub-id pub-id-type="pmid">24856828</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lupski</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders</article-title>
<source/>Cell
          <year>2007</year>
<volume>131</volume>
<issue>7</issue>
<fpage>1235</fpage>
<lpage>1247</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.11.037</pub-id>
<pub-id pub-id-type="pmid">18160035</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lev</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Roncevic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ickowicz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Melamed</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Offen</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Role of DJ-1 in Parkinson’s disease</article-title>
<source/>J Mol Neurosci MN
          <year>2006</year>
<volume>29</volume>
<issue>3</issue>
<fpage>215</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1385/JMN:29:3:215</pub-id>
<pub-id pub-id-type="pmid">17085780</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Cookson</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Gene expression in the Parkinson’s disease brain</article-title>
<source/>Brain Res Bull
          <year>2012</year>
<volume>88</volume>
<issue>4</issue>
<fpage>302</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresbull.2011.11.016</pub-id>
<pub-id pub-id-type="pmid">22173063</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tomiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hatano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Atsumi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitaguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miyajima</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism</article-title>
<source/>Neurology
          <year>2005</year>
<volume>64</volume>
<issue>11</issue>
<fpage>1955</fpage>
<lpage>1957</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000164009.36740.4E</pub-id>
<pub-id pub-id-type="pmid">15955953</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Verbitsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kisselev</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Browne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mejia-Sanatana</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Cote</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Frucht</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fahn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marder</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Genome-wide association study identifies candidate genes for Parkinson’s disease in an Ashkenazi Jewish population</article-title>
<source/>BMC Med Genet
          <year>2011</year>
<volume>12</volume>
<fpage>104</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-12-104</pub-id>
<pub-id pub-id-type="pmid">21812969</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Verbitsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kisselev</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mejia-Santana</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cote</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fahn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marder</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson’s disease among Ashkenazi Jews</article-title>
<source/>Mol Genet Genom Med
          <year>2013</year>
<volume>1</volume>
<issue>3</issue>
<fpage>142</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1002/mgg3.18</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubbe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>Recent advances in Parkinson’s disease genetics</article-title>
<source/>J Neurol
          <year>2014</year>
<volume>261</volume>
<issue>2</issue>
<fpage>259</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-013-7003-2</pub-id>
<pub-id pub-id-type="pmid">23798000</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucking</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vaughan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Michele</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Harhangi</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Meco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Denefle</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<collab>French Parkinson’s Disease Genetics Study G</collab>
<collab>European Consortium on Genetic Susceptibility in Parkinson’s D</collab>
</person-group>
<article-title>Association between early-onset Parkinson’s disease and mutations in the parkin gene</article-title>
<source/>N Engl J Med
          <year>2000</year>
<volume>342</volume>
<issue>21</issue>
<fpage>1560</fpage>
<lpage>1567</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM200005253422103</pub-id>
<pub-id pub-id-type="pmid">10824074</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lupianez</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Spielmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mundlos</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Breaking TADs: how alterations of chromatin domains result in disease</article-title>
<source/>Trends Genet TIG
          <year>2016</year>
<volume>32</volume>
<issue>4</issue>
<fpage>225</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2016.01.003</pub-id>
<pub-id pub-id-type="pmid">26862051</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacDonald</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ziman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Feuk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>The Database of Genomic Variants: a curated collection of structural variation in the human genome</article-title>
<source/>Nucleic Acids Res
          <year>2014</year>
<volume>42</volume>
<issue>Database issue</issue>
<fpage>D986</fpage>
<lpage>D992</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkt958</pub-id>
<pub-id pub-id-type="pmid">24174537</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macedo</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Verbaan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>van Rooden</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Uras</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Groen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rizzu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van Hilten</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Heutink</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson’s disease</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2009</year>
<volume>24</volume>
<issue>2</issue>
<fpage>196</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="doi">10.1002/mds.22287</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahul-Mellier</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Fauvet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gysbers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dikiy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Oueslati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Georgeon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lamontanara</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Bisquertt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eliezer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hantschel</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Lashuel</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<issue>11</issue>
<fpage>2858</fpage>
<lpage>2879</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt674</pub-id>
<pub-id pub-id-type="pmid">24412932</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marongiu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brancati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ialongo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ceccarini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scarciolla</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Capalbo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Benti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pezzoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Goldwurm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum</article-title>
<source/>Hum Mutat
          <year>2007</year>
<volume>28</volume>
<issue>1</issue>
<fpage>98</fpage>
<pub-id pub-id-type="doi">10.1002/humu.9472</pub-id>
<pub-id pub-id-type="pmid">17154281</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marttinen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kurkinen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Soininen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Haapasalo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hiltunen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Synaptic dysfunction and septin protein family members in neurodegenerative diseases</article-title>
<source/>Mol Neurodegener
          <year>2015</year>
<volume>10</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-015-0013-z</pub-id>
<pub-id pub-id-type="pmid">25888325</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mata</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Coto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Blazquez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guisasola</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Salvador</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism</article-title>
<source/>Neurosci Lett
          <year>2005</year>
<volume>380</volume>
<issue>3</issue>
<fpage>257</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2005.01.051</pub-id>
<pub-id pub-id-type="pmid">15862897</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehler</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Gokhan</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat</article-title>
<source/>Trends Neurosci
          <year>2000</year>
<volume>23</volume>
<issue>12</issue>
<fpage>599</fpage>
<lpage>605</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-2236(00)01705-7</pub-id>
<pub-id pub-id-type="pmid">11137149</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michel</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Hunot</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Understanding Dopaminergic Cell Death Pathways in Parkinson Disease</article-title>
<source/>Neuron
          <year>2016</year>
<volume>90</volume>
<issue>4</issue>
<fpage>675</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2016.03.038</pub-id>
<pub-id pub-id-type="pmid">27196972</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mok</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Sheerin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Simon-Sanchez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Salaka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chester</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Escott-Price</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mantripragada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Noyce</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Mencacci</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Lubbe</surname>
<given-names>SJ</given-names>
</name>
<collab>International Parkinson’s Disease Genomics C</collab>
<name>
<surname>Williams-Gray</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>van Dijk</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Berendse</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Heutink</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Corvol</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Cormier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lesage</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brockmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Foltynie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Limousin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Sawcer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Plagnol</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>NW</given-names>
</name>
</person-group>
<article-title>Deletions at 22q11.2 in idiopathic Parkinson’s disease: a combined analysis of genome-wide association data</article-title>
<source/>Lancet Neurol
          <year>2016</year>
<pub-id pub-id-type="pmid">27017469</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Molecular pathophysiology of Parkinson’s disease</article-title>
<source/>Annu Rev Neurosci
          <year>2005</year>
<volume>28</volume>
<fpage>57</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.28.061604.135718</pub-id>
<pub-id pub-id-type="pmid">16022590</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moura</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Junior</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>de Rosso</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Nicaretta</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Jose Silva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Santos-Reboucas</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Pimentel</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Exon dosage variations in Brazilian patients with Parkinson’s disease: analysis of SNCA, PARKIN, PINK1 and DJ-1 genes</article-title>
<source/>Dis Markers
          <year>2012</year>
<volume>32</volume>
<issue>3</issue>
<fpage>173</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1155/2012/218642</pub-id>
<pub-id pub-id-type="pmid">22377733</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Catechol-O-methyltransferase inhibitors in Parkinson’s disease</article-title>
<source/>Drugs
          <year>2015</year>
<volume>75</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1007/s40265-014-0343-0</pub-id>
<pub-id pub-id-type="pmid">25559423</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Bohnen</surname>
<given-names>NI</given-names>
</name>
</person-group>
<article-title>Cholinergic dysfunction in Parkinson’s disease</article-title>
<source/>Curr Neurol Neurosci Rep
          <year>2013</year>
<volume>13</volume>
<issue>9</issue>
<fpage>377</fpage>
<pub-id pub-id-type="doi">10.1007/s11910-013-0377-9</pub-id>
<pub-id pub-id-type="pmid">23943367</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Cottle</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gysbers</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies</article-title>
<source/>Acta Neuropathol Commun
          <year>2013</year>
<volume>1</volume>
<issue>1</issue>
<fpage>11</fpage>
<pub-id pub-id-type="doi">10.1186/2051-5960-1-11</pub-id>
<pub-id pub-id-type="pmid">24252509</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mutez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lepretre</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Le Rhun</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Larvor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Duflot</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mouroux</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kerckaert</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Figeac</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dujardin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Destee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chartier-Harlin</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes</article-title>
<source/>Hum Mutat
          <year>2011</year>
<volume>32</volume>
<issue>4</issue>
<fpage>E2079</fpage>
<lpage>E2090</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21459</pub-id>
<pub-id pub-id-type="pmid">21412942</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakatani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kumai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mizuhara</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Minaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon</article-title>
<source/>Dev Biol
          <year>2010</year>
<volume>339</volume>
<issue>1</issue>
<fpage>101</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1016/j.ydbio.2009.12.017</pub-id>
<pub-id pub-id-type="pmid">20035737</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishioka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kitami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tomiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Imoto</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Inazawa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Clinical heterogeneity of α-synuclein gene duplication in Parkinson’s disease</article-title>
<source/>Ann Neurol
          <year>2006</year>
<volume>59</volume>
<issue>2</issue>
<fpage>298</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1002/ana.20753</pub-id>
<pub-id pub-id-type="pmid">16358335</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishioka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ishiwata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kitagawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kono</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Obi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takanashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Expanding the clinical phenotype of SNCA duplication carriers</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2009</year>
<volume>24</volume>
<issue>12</issue>
<fpage>1811</fpage>
<lpage>1819</lpage>
<pub-id pub-id-type="doi">10.1002/mds.22682</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nuytemans</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Meeus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Crosiers</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brouwers</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goossens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pals</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pickut</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Van den Broeck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corsmit</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cras</surname>
<given-names>P</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Del-Favero</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Van Broeckhoven</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Theuns</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population</article-title>
<source/>Human Mutat
          <year>2009</year>
<volume>30</volume>
<issue>7</issue>
<fpage>1054</fpage>
<lpage>1061</lpage>
<pub-id pub-id-type="doi">10.1002/humu.21007</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
</person-group>
<article-title>Chromosome 22q11.2 deletion may contain a locus for recessive early-onset Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
          <year>2014</year>
<volume>20</volume>
<issue>9</issue>
<fpage>945</fpage>
<lpage>946</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.06.020</pub-id>
<pub-id pub-id-type="pmid">25001314</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olgiati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Breedveld</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Graafland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eussen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Douben</surname>
<given-names>H</given-names>
</name>
<name>
<surname>de Klein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Onofrj</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Early-onset parkinsonism caused by alpha-synuclein gene triplication: clinical and genetic findings in a novel family</article-title>
<source/>Parkinsonism Relat Disord
          <year>2015</year>
<volume>21</volume>
<issue>8</issue>
<fpage>981</fpage>
<lpage>986</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.06.005</pub-id>
<pub-id pub-id-type="pmid">26077166</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Nance</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hubble</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Koller</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hiner</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Ondo</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>FH</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Scott</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Mastaglia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stajich</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Booze</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Winn</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Haines</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pericak-Vance</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Parkin mutations and susceptibility alleles in late-onset Parkinson’s disease</article-title>
<source/>Ann Neurol
          <year>2003</year>
<volume>53</volume>
<issue>5</issue>
<fpage>624</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1002/ana.10524</pub-id>
<pub-id pub-id-type="pmid">12730996</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Avallone</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sheidley</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Pinsky</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bergin</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Duffy</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Eksioglu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Hisama</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Irons</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>James</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kothare</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khwaja</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Loddenkemper</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Markowitz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Megerian</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Neilan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Raffalli</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rollins</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sarco</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schonwald</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Soul</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stoler</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Takeoka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Urion</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Poduri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Copy number variation plays an important role in clinical epilepsy</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>75</volume>
<issue>6</issue>
<fpage>943</fpage>
<lpage>958</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24178</pub-id>
<pub-id pub-id-type="pmid">24811917</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pamphlett</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Morahan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Luquin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>An approach to finding brain-situated mutations in sporadic Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
          <year>2012</year>
<volume>18</volume>
<issue>1</issue>
<fpage>82</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2011.08.024</pub-id>
<pub-id pub-id-type="pmid">21917499</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pankratz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kissell</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Pauciulo</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Halter</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Marder</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Foroud</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>WC</given-names>
</name>
<collab>Parkinson Study Group PI</collab>
</person-group>
<article-title>Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations</article-title>
<source/>Neurology
          <year>2009</year>
<volume>73</volume>
<issue>4</issue>
<fpage>279</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181af7a33</pub-id>
<pub-id pub-id-type="pmid">19636047</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pankratz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dumitriu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hetrick</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Latourelle</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Wilk</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Halter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Doheny</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Gusella</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Nichols</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Foroud</surname>
<given-names>T</given-names>
</name>
<name>
<surname>DeStefano</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Psg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>GenePd Investigators</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Molecular Genetic</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Copy number variation in familial Parkinson disease</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>8</issue>
<fpage>e20988</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0020988</pub-id>
<pub-id pub-id-type="pmid">21829596</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perandones</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Giugni</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Raina</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>De Jorge</surname>
<given-names>Lopez L</given-names>
</name>
<name>
<surname>Volpini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zabetian</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Mata</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Caputo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corach</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Radrizzani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Micheli</surname>
<given-names>FE</given-names>
</name>
</person-group>
<article-title>Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism</article-title>
<source/>Parkinsonism Relat Disord
          <year>2014</year>
<volume>20</volume>
<issue>5</issue>
<fpage>558</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.11.014</pub-id>
<pub-id pub-id-type="pmid">24552873</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perandones</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Farini</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Pellene</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Sáenz Farret</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cuevas</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease in a patient with 22q11.2 deletion syndrome: the relevance of detecting mosaicisms by means of cell-by-cell evaluation techniques. Single Cell</article-title>
<source/>Biol
          <year>2015</year>
<volume>4</volume>
<fpage>123</fpage>
</element-citation>
</ref>
<ref id="CR118">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Periquet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lucking</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vaughan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Michele</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Horstink</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Illarioshkin</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Borg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brefel-Courbon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Denefle</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Meco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Breteler</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<collab>French Parkinson’s Disease Genetics Study Group</collab>
<collab>The European Consortium on Genetic Susceptibility in Parkinson’s D</collab>
</person-group>
<article-title>Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects</article-title>
<source/>Am J Human Genet
          <year>2001</year>
<volume>68</volume>
<issue>3</issue>
<fpage>617</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="doi">10.1086/318791</pub-id>
<pub-id pub-id-type="pmid">11179010</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pogson</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Ivatt</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Whitworth</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of PINK1-related neurodegeneration</article-title>
<source/>Curr Neurol Neurosci Rep
          <year>2011</year>
<volume>11</volume>
<issue>3</issue>
<fpage>283</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="doi">10.1007/s11910-011-0187-x</pub-id>
<pub-id pub-id-type="pmid">21331528</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polymeropoulos</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Lavedan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leroy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Dehejia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dutra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Root</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rubenstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stenroos</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Chandrasekharappa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Athanassiadou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Papapetropoulos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Lazzarini</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Duvoisin</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Di Iorio</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Golbe</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Nussbaum</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease</article-title>
<source/>Science
          <year>1997</year>
<volume>276</volume>
<issue>5321</issue>
<fpage>2045</fpage>
<lpage>2047</lpage>
<pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id>
<pub-id pub-id-type="pmid">9197268</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reglodi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lubics</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tamas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Szalontay</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lengvari</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson’s disease</article-title>
<source/>Behav Brain Res
          <year>2004</year>
<volume>151</volume>
<issue>1–2</issue>
<fpage>303</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2003.09.007</pub-id>
<pub-id pub-id-type="pmid">15084446</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reglodi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lubics</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tamas</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo</article-title>
<source/>Curr Pharm Des
          <year>2011</year>
<volume>17</volume>
<issue>10</issue>
<fpage>962</fpage>
<lpage>972</lpage>
<pub-id pub-id-type="doi">10.2174/138161211795589355</pub-id>
<pub-id pub-id-type="pmid">21524257</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rehman</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Dhamija</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>22q11.2 deletion syndrome presenting with early-onset Parkinson’s disease</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2015</year>
<volume>30</volume>
<issue>9</issue>
<fpage>1289</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26305</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Braithwaite</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Skipper</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hulihan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Nishioka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maraganore</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Larvor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chartier-Harlin</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Langston</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Gwinn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Genomic investigation of α-synuclein multiplication and parkinsonism</article-title>
<source/>Ann Neurol
          <year>2008</year>
<volume>63</volume>
<issue>6</issue>
<fpage>743</fpage>
<lpage>750</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21380</pub-id>
<pub-id pub-id-type="pmid">18571778</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rovelet-Lecrux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Deramecourt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Legallic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maurage</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Le Ber</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Frebourg</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hannequin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pasquier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Campion</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease</article-title>
<source/>Neurobiol Dis
          <year>2008</year>
<volume>31</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2008.03.004</pub-id>
<pub-id pub-id-type="pmid">18479928</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samaranch</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lorenzo-Betancor</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Arbelo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lorenzo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Irigoyen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Marrero</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Isla</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Herrera-Henriquez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>PINK1-linked parkinsonism is associated with Lewy body pathology</article-title>
<source/>Brain J Neurol
          <year>2010</year>
<volume>133</volume>
<issue>Pt 4</issue>
<fpage>1128</fpage>
<lpage>1142</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awq051</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scuderi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>La Cognata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Drago</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>D’Agata</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain</article-title>
<source/>BioMed Res Int
          <year>2014</year>
<volume>2014</volume>
<fpage>690796</fpage>
<pub-id pub-id-type="doi">10.1155/2014/690796</pub-id>
<pub-id pub-id-type="pmid">25136611</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kagaya</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Funayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tomiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hattori</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Clinical course of the first Asian family with Parkinsonism related to SNCA triplication</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2010</year>
<volume>25</volume>
<issue>16</issue>
<fpage>2871</fpage>
<lpage>2875</lpage>
<pub-id pub-id-type="doi">10.1002/mds.23313</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shadrina</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Semenova</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Slominsky</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Bagyeva</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Illarioshkin</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>S</given-names>
<suffix>II</suffix>
</name>
<name>
<surname>Limborska</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage</article-title>
<source/>BMC Med Genet
          <year>2007</year>
<volume>8</volume>
<fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-8-6</pub-id>
<pub-id pub-id-type="pmid">17324265</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw-Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Redon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rickman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Willatt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fiegler</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Firth</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sanlaville</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Colleaux</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bobrow</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>NP</given-names>
</name>
</person-group>
<article-title>Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features</article-title>
<source/>J Med Genet
          <year>2004</year>
<volume>41</volume>
<issue>4</issue>
<fpage>241</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2003.017731</pub-id>
<pub-id pub-id-type="pmid">15060094</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Two Parkinson’s disease patients with alpha-synuclein gene duplication and rapid cognitive decline</article-title>
<source/>Mov Disord Off J Mov Disord Soc
          <year>2010</year>
<volume>25</volume>
<issue>7</issue>
<fpage>957</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.1002/mds.23043</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shivers</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Nikolopoulou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Machlovi</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Vallabhajosula</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Figueiredo-Pereira ME (2014) PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2</article-title>
<source/>Biochim Biophys Acta
          <year>2014</year>
<volume>9</volume>
<fpage>1707</fpage>
<lpage>1719</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2014.06.020</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon-Sanchez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matarin Mdel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genomewide SNP assay reveals mutations underlying Parkinson disease</article-title>
<source/>Hum Mutat
          <year>2008</year>
<volume>29</volume>
<issue>2</issue>
<fpage>315</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20626</pub-id>
<pub-id pub-id-type="pmid">17994548</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon-Sanchez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bras</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Paisan-Ruiz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lichtner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Kruger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Federoff</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Goate</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perlmutter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bonin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nalls</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Illig</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gieger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Steffens</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okun</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Racette</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Cookson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Foote</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Traynor</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arepalli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zonozi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gwinn</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van der Brug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chanock</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Schatzkin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hollenbeck</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Lorenz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deuschl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Riess</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Gasser</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Genome-wide association study reveals genetic risk underlying Parkinson’s disease</article-title>
<source/>Nat Genet
          <year>2009</year>
<volume>41</volume>
<issue>12</issue>
<fpage>1308</fpage>
<lpage>1312</lpage>
<pub-id pub-id-type="doi">10.1038/ng.487</pub-id>
<pub-id pub-id-type="pmid">19915575</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sindi</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Tannenberg</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Dodd</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>Role for the neurexin-neuroligin complex in Alzheimer’s disease</article-title>
<source/>Neurobiol Aging
          <year>2014</year>
<volume>35</volume>
<issue>4</issue>
<fpage>746</fpage>
<lpage>756</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.09.032</pub-id>
<pub-id pub-id-type="pmid">24211009</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hague</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kachergus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hulihan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peuralinna</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dutra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nussbaum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maraganore</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cookson</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Muenter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baptista</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Blancato</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gwinn-Hardy</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>α-Synuclein locus triplication causes Parkinson’s disease</article-title>
<source/>Science
          <year>2003</year>
<volume>302</volume>
<issue>5646</issue>
<fpage>841</fpage>
<pub-id pub-id-type="doi">10.1126/science.1090278</pub-id>
<pub-id pub-id-type="pmid">14593171</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sironi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Trotta</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ciccone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Della Mina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Meucci</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sacilotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Primignani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Coviello</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Pezzoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goldwurm</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>α-Synuclein multiplication analysis in Italian familial Parkinson disease</article-title>
<source/>Parkinsonism Relat Disord
          <year>2010</year>
<volume>16</volume>
<issue>3</issue>
<fpage>228</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2009.09.008</pub-id>
<pub-id pub-id-type="pmid">19833540</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soldner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stelzer</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shivalila</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Latourelle</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Barrasa</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Goldmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Jaenisch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression</article-title>
<source/>Nature
          <year>2016</year>
<volume>533</volume>
<issue>7601</issue>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1038/nature17939</pub-id>
<pub-id pub-id-type="pmid">27096366</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Son</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kawamata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sulzer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Degiorgio</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons</article-title>
<source/>J Neurochem
          <year>2005</year>
<volume>94</volume>
<issue>4</issue>
<fpage>1040</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03257.x</pub-id>
<pub-id pub-id-type="pmid">16092945</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spielmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mundlos</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Structural variations, the regulatory landscape of the genome and their alteration in human disease</article-title>
<source/>BioEssays News Rev Mol Cell Dev Biol
          <year>2013</year>
<volume>35</volume>
<issue>6</issue>
<fpage>533</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="doi">10.1002/bies.201200178</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spielmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mundlos</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Looking beyond the genes: the role of non-coding variants in human disease</article-title>
<source/>Hum Mol Genet
          <year>2016</year>
<volume>25</volume>
<issue>R2</issue>
<fpage>R157</fpage>
<lpage>R165</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddw205</pub-id>
<pub-id pub-id-type="pmid">27354350</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefanis</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>α-Synuclein in Parkinson’s disease</article-title>
<source/>Cold Spring Harbor Perspect Med
          <year>2012</year>
<volume>2</volume>
<issue>2</issue>
<fpage>a009399</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a009399</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>YZ</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Identifying distinct candidate genes for early Parkinson’s disease by analysis of gene expression in whole blood</article-title>
<source/>Neuro endocrinology letters
          <year>2014</year>
<volume>35</volume>
<issue>5</issue>
<fpage>398</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="pmid">25275262</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutherland</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Matigian</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Chalk</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Silburn</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Mackay-Sim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Mellick</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>A cross-study transcriptional analysis of Parkinson’s disease</article-title>
<source/>PLoS One
          <year>2009</year>
<volume>4</volume>
<issue>3</issue>
<fpage>e4955</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004955</pub-id>
<pub-id pub-id-type="pmid">19305504</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toft</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>OA</given-names>
</name>
</person-group>
<article-title>Copy number variation in Parkinson’s disease</article-title>
<source/>Genome medicine
          <year>2010</year>
<volume>2</volume>
<issue>9</issue>
<fpage>62</fpage>
<pub-id pub-id-type="pmid">20828427</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Advances in the genetics of Parkinson disease</article-title>
<source/>Nat Rev Neurol
          <year>2013</year>
<volume>9</volume>
<issue>8</issue>
<fpage>445</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2013.132</pub-id>
<pub-id pub-id-type="pmid">23857047</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<mixed-citation publication-type="other">Troiano AR, Cazeneuve C, Le Ber I, Bonnet AM, Lesage S, Brice A (2008) Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 71(16):1295; author reply 1295. doi:10.1212/01.wnl.0000338435.78120.0f</mixed-citation>
</ref>
<ref id="CR148">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ikeuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ouchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kasuga</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shiga</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Atsumi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication</article-title>
<source/>Neurology
          <year>2008</year>
<volume>71</volume>
<issue>16</issue>
<fpage>1289</fpage>
<lpage>1291</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000327607.28928.e6</pub-id>
<pub-id pub-id-type="pmid">18852445</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valente</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Abou-Sleiman</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Caputo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Muqit</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gispert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Del Turco</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bentivoglio</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nussbaum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gonzalez-Maldonado</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Deller</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Salvi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cortelli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gilks</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Latchman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Auburger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>NW</given-names>
</name>
</person-group>
<article-title>Hereditary early-onset Parkinson’s disease caused by mutations in PINK1</article-title>
<source/>Science
          <year>2004</year>
<volume>304</volume>
<issue>5674</issue>
<fpage>1158</fpage>
<lpage>1160</lpage>
<pub-id pub-id-type="doi">10.1126/science.1096284</pub-id>
<pub-id pub-id-type="pmid">15087508</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Abel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Veerhuis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Dijk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oudejans</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Direct downregulation of CNTNAP2 by STOX1A is associated with Alzheimer’s disease</article-title>
<source/>J Alzheimer’s Dis JAD
          <year>2012</year>
<volume>31</volume>
<issue>4</issue>
<fpage>793</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="pmid">22728895</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Heide</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Smidt</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>The BCL2 code to dopaminergic development and Parkinson’s disease</article-title>
<source/>Trends Mol Med
          <year>2013</year>
<volume>19</volume>
<issue>4</issue>
<fpage>211</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2013.02.003</pub-id>
<pub-id pub-id-type="pmid">23523055</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Duijn</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Galjaard</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Houwing-Duistermaat</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Snijders</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Testers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Breedveld</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Horstink</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sandkuijl</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Oostra</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Heutink</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36</article-title>
<source/>Am J Hum Genet
          <year>2001</year>
<volume>69</volume>
<issue>3</issue>
<fpage>629</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1086/322996</pub-id>
<pub-id pub-id-type="pmid">11462174</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Kampen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Baranowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson’s disease</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>5</issue>
<fpage>e97032</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0097032</pub-id>
<pub-id pub-id-type="pmid">24804730</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilarino-Guell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ben Yahmed</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kefi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heckman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Hulihan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Amouri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mash</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Hentati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Farrer</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>ATP13A2 variability in Parkinson disease</article-title>
<source/>Hum Mutat
          <year>2009</year>
<volume>30</volume>
<issue>3</issue>
<fpage>406</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1002/humu.20877</pub-id>
<pub-id pub-id-type="pmid">19085912</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson’s disease in Chinese: an independent pathogenic role</article-title>
<source/>Brain Res
          <year>2010</year>
<volume>1358</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.08.060</pub-id>
<pub-id pub-id-type="pmid">20800584</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nuytemans</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bademci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jauregui</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zuchner</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>High-resolution survey in familial Parkinson disease genes reveals multiple independent copy number variation events in PARK2</article-title>
<source/>Hum Mutat
          <year>2013</year>
<volume>34</volume>
<issue>8</issue>
<fpage>1071</fpage>
<lpage>1074</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22344</pub-id>
<pub-id pub-id-type="pmid">23616242</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neuroinflammation in Parkinson’s disease and its potential as therapeutic target</article-title>
<source/>Transl Neurodegener
          <year>2015</year>
<volume>4</volume>
<fpage>19</fpage>
<pub-id pub-id-type="doi">10.1186/s40035-015-0042-0</pub-id>
<pub-id pub-id-type="pmid">26464797</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winklhofer</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Haass</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in Parkinson’s disease</article-title>
<source/>Biochim Biophys Acta
          <year>2010</year>
<volume>1802</volume>
<issue>1</issue>
<fpage>29</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2009.08.013</pub-id>
<pub-id pub-id-type="pmid">19733240</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Elias</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Woldman</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pifl</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gygi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Geula</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yankner</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>The Parkinson’s disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis</article-title>
<source/>Hum Mol Genet
          <year>2005</year>
<volume>14</volume>
<issue>9</issue>
<fpage>1231</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddi134</pub-id>
<pub-id pub-id-type="pmid">15790595</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yonova-Doing</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Atadzhanov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Musonda</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Simons</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Breedveld</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Oostra</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
          <year>2012</year>
<volume>18</volume>
<issue>5</issue>
<fpage>567</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.02.018</pub-id>
<pub-id pub-id-type="pmid">22445250</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaleski</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shugar</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome</article-title>
<source/>Am J Med Genet Part A
          <year>2009</year>
<volume>149A</volume>
<issue>3</issue>
<fpage>525</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32650</pub-id>
<pub-id pub-id-type="pmid">19208384</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarrei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Merico</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>A copy number variation map of the human genome</article-title>
<source/>Nat Rev Genet
          <year>2015</year>
<volume>16</volume>
<issue>3</issue>
<fpage>172</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3871</pub-id>
<pub-id pub-id-type="pmid">25645873</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>